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ABSTRACT 
Congenital Hypomyelination (CH) IS the most severe 
demyelinating form of Hereditary Motor and Sensory Neuropathies and 
manifests at birth in human. Some subtypes of CH are due to dominant 
mutations in the gene coding for PO glycoprotein, which functions as a 
homophilic adhesion protein, responsible for compaction of opposing 
myelin lamellae. By homologous recombination in ES cells, we have 
generated a mouse containing a nonsense mutation in the intracellular 
portion of PO (Q215X) that, in the heterozygous state, is associated with 
CH neuropathy in humans. This mutation is predicted to encode a 
truncated PO protein, lacking part of the cytoplasmic domain. Expression 
analysis demonstrated that Q215X heterozygous mice produce both 
wildtype PO and a smaller, truncated PO glycoprotein; furthermore, the 
levels of mRNA and protein produced by the mutated allele are less 
abundant, relative to the wildtype. We demonstrated then that this 
reduction in mRNA and protein levels could be paIiially explained by 
inefficient transcription of the mutated allele, due to the presence of a 
LoxP site with intron 5. Behavioral analysis of the Q215X1+ mice revealed 
reduced motor performance at 11 days after birth. Morphological analysis 
performed on sciatic nerves of mice between PI and P 14 revealed defects 
in the process of axonal sorting by Schwann cells, with the presence of 
bundles of mixed large and small calibre axons surrounded, but not 
ensheathed, by single Schwann cells. These morphogical defects are 
rescued after the second week of life: sciatic nerves from adult mice, in 
fact, show only mild hypomyelination, which is much less severe than the 
morphology reported in patients. From these preliminary data, we 
conclude that the Q215X mutation results in a truncated PO protein; since 
the phenotype ofQ215X1+ mice and PO +1- mice differs, Q215X probably 
produces a gain of function. Finally, we studied in vivo the intracellular 
location of the truncated protein, in order to clarify aspects of the 
pathogenetic mechanism of the Q215X PO mutation: we found that the 
mutated protein is not properly trafficked within Schwann cells, being 
partially retained in the ER compartment. The phenotype we have 
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observed in the mutant mice presents similarities to other hypomyelinating 
mice that carry mutations in different genes, that are all involved in the 
laminin pathway: this suggests that mutant PO may interfere with laminin 
signaling, required for the correct timing of axonal sorting by Schwann 
cells. Thus, from these data we conclude that the Q215X mouse is a partial 
model of Congenital Hypomyelination, less severely affected, if compared 
to human patients. This difference in disease severity could be partially 
explained by the inefficient transcription of the Q215X allele. Thus, we 
believe that the mechanism of this hypomyelination is likely to be related 
to the mechanism of the more severe neuropathy in human. This mouse 
will be useful to reveal the pathogenesis of the mutation. 
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1. INTRODUCTION 
1.1 The Nervous system 
Neurons and glia, together with other supp0l1ing cells like blood 
vessels, meninges, immune cells and fibroblasts are components of the 
Nervous System 
• 1.1.1 Nerve Cells 
Within a neuron, four morphologically different regions can be 
distinguished: the cell body (or the perikaryon), the dendrites, the axon 
and the presynaptic terminal of the axon. What differentiates a nerve cell 
from other cell types is the ability to generate electrical signals. The 
metabolic center of the neuron, the perikalyon, usually gives rise to a 
series of extensions, the dendrites, that form the receptive apparatus of the 
neurons. The other characteristic neuronal structure, the axoll , the 
conducting unit of the neuron, is a tubular process that can extend for a 
long distance in the body. The high speed conduction of the action 
potential is facilitated by the myelin sheath which is present in the Central 
Nervous System (CNS) and in the Peripheral Nervous System (PNS), 
except at the level of the Node of Ranvier. Close to its end the axon 
divides into many specialised extremities, called presynaptic terminals, 
which constitute the transmitting elements of the neuron. It is through 
them that a neuron contacts and transmits information to the receptive 
surfaces of any effector cells. The point of contact is called synapse. 
Three different components give rise to a synapse: the presynaptic 
terminal of a cell, the receptive surface of the other cell and the space 
between them, the synaptic cleft. The terminals of the presynaptic neuron 
sometimes contact the postsynaptic neuron directly on its cell body; more 
commonly they make contact with dendrites. In the case of the motor 
axons of the PNS, the receptive cell is a skeletal muscle cell and the 
synaptic unit is referred to as the neuromuscular junction. In each neuronal 
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cell infOlmation goes from the cell body and dendrites, to the region from 
where the impulse initiates and finally to the presynaptic site of the axon 
that communicates with other cells. Between nerve cells there is no 
cytoplasmic continuity and each cell has specific and precise connections 
only with some nerve cells and not with others. 
On the basis of the number of processes that arise from the cell 
body, neurons are classified into three groups, unipolar, bipolar and 
multipolar. Multipolar neurons predominate in the vertebrate nervous 
system, they have one or more dendtitic processes and a single axon. In a 
typical multipolar cell, dendrites emerge from all parts of the neuronal 
body. Even within the category of the multipolar neurons the size and the 
shape of different cells vary greatly. Different types of multipolar cells 
account for all of the distinguishable neuronal types. The morphological 
differences among multipolar cells are due largely to vatiations in the 
number and length of dendtites and length of the axon. The number and 
extent of dendtitic processes in a given cell correlate with the number of 
synaptic contacts that other neurons make on that cell, while the length of 
the axon reflects the signalling function of a neuron. 
• 1.1.2 Glial Cells 
Glial cells are found contacting nerve cell bodies and also 
contacting and sometimes ensheathing axons, where they serve different 
functions: they provide myelin, they support brain structure, they remove 
debris coming from neuronal death or injury, they drive the migration of 
neurons and guide the outgrowth ofaxons, they provide noutishment for 
nerve cells and finally they modulate synaptic transmission. 
Glial cells are generally divided into macroglia and microglia. The 
macroglia include myelin forming cells: Oligodendrocytes (OL) in the 
CNS and Schwann cells (SC) in the PNS, astrocytes and ependymal cells. 
Microglia includes several phagocytic cells that can be mobilised after 
injuties, infections or other diseases. 
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The major function of OL and SC is to generate myelin 
respectively in the CNS and in the PNS, although in the PNS SC also 
surround small calibre axons without myelinating them, providing a 
support and protective function. They fonn this sheath by spirally 
wrapping their plasma membrane. Probably the major difference between 
these two cell types is that one OL can envelop several axons at the same 
time in the CNS and make myelin around them, on the contrary a single 
SC myelinates only one axon, with a diameter larger than 1 J.lm (Friede and 
Samorajski, 1968). 
1.2 The Peripheral Nervous System (PNS) 
The peripheral nervous system (PNS) includes the cranial nerves, 
the spinal nerves with their roots, the peripheral nerves and the peripheral 
components of the autonomic nervous system and the enteric nervous 
system. Spinal alfa-motoneurons, which extend axons into the PNS, have 
their soma located in the ventral horn of the spinal cord and their axons 
leave the CNS through the ventral roots. Primary sensory neurons are 
located in the dorsal root ganglia (DRG) of the PNS and project axons 
both centrally to the CNS and peripherally through the dorsal roots to their 
peripheral targets. The dorsal and ventral roots are attached to the spinal 
cord and the attachment site is considered as the border between the 
peripheral and the central nervous systems. Of note that, while axons 
penetrate the transition zone, the surrounding glia cells do not. As a 
consequence, Schwann cells (SCs), the glia cells of the PNS, are only 
associated with the parts of the axons that are located in the PNS. The 
outer connective tissue layer of the CNS, the dural sheath, becomes 
merged with the outer connective tissue layer of peripheral nerves, the 
epineurium, where the dorsal and ventral roots merge to form a spinal 
nerve. As the spinal nerves leave the spinal canal, they quickly divide into 
dorsal and ventral rami. The dorsal rami supply the back, while the ventral 
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rami send projections to the ventrolateral part of the body wall and the 
limbs. The ventral rami supplying the limbs form plexuses at the cervical 
and lumbosacral regions, from which the major peripheral nerves emerge 
to reach the limbs. 
The epineurium, the penneunum and the endoneurium, three 
layers of compact connective tissue separate and protect single nerve 
fibers. The epineurium surrounds the fascicles of the peripheral nerve; it is 
constituted by fibroblasts lacking a basal lamina and by collagen type I 
and III. Of note that the epineurium is the only part of the PNS where a 
lymphatic capillary network is present and is connected to regional lymph 
nodes. Two other components are relevant for the epinuerium 
histoarchitecture: first, the vasa neljJorllm, a network of arterioles and 
venules that provides blood support and that extends to the perineurium 
and the endoneurium; second, variable amounts of fat, working as pillows 
to protect the fascicles against damage by compression. 
Six to eight layers of epithelial cells constitute the perinuerium. All 
the layers consist of concentric flattened epithelial cells with a basal 
lamina connected to each other by tight junctions and gap junctions. Of 
these cell layers, both the inner and the outer produce an organized basal 
lamina, made of collagen type IV fibers, fibronectin and proteoglycan. 
Two main functions are accomplished by the perineurium: first, to allow a 
selective transport mechanism, able to restIicts transfer of molecules into 
the endoneurium; second to protect nerve fibers from damage through an 
organized structure of collagen layers (Parmantier et aI., 1999). 
The endoneurium, the intrafascicular compartment of the nerve, is 
made of collagen fibrils running parallel along the nerves. It reaches 50% 
of the intrafascicular space, giving support and protection to the fascicles. 
Embedded in the endoneurium are axons ensheathed by SC. EndoneuIial 
fibroblasts are the main producers of the collagen that is present in this 
structure. 
Finally, within the peIipheral nerves, SCs are the major cellular 
component of the intrafascicular space, together with a smaller number of 
endoneurial fibroblasts. Rows of SCs are arranged longitudinally along the 
axons, fOlming myelin sheaths around them. As a rule, large caliber axons 
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are sUlTounded by myelin, whereas small caliber axons are segregated by 
SCs, but not myelinated. Around the SCs, a carbohydrate rich basal lamina 
covers the surface. 
1.3 Myelin 
Myelin is one of the fundamental adaptations of vertebrates: it is a 
spiraled extension around an axon of, respectively, the Schwann cell 
plasma membrane in the PNS and the oligodendrocyte plasma membrane 
in the CNS. Myelin promotes rapid and repetitive communication between 
neurons and it modulates the maturation and survival ofaxons. Neurons 
communicate by depolarizing the electrical potential of their axons; this 
occurs through channel-mediated exchange ofNa+ in an energy dependent 
manner. Rapid unmyelinated axonal communication would demand 
energy and space requirements that are not consistent with evolution of the 
complex mammalian brain. It was therefore advantageous to evolve a 
mechanism to propagate neuronal communication through thin axons in a 
more efficient manner. Myelin-forming cells serve this function by 
producing a series of discontinuous insulation units called internodes 
along single axons. 
Each myelin internode can be divided into two structurally and 
functionally distinct domains: compact myelin and non-compact myelin 
(the paranodal and Schmidt-Lantermann regions). Compact myelin 
inhibits ion exchange during nerve conduction, while the paranodes, 
which demarcate the longitudinal ends of each internode, facilitate ion 
exchange at the Node of Ranvier, a part of the axon that separates each 
internode. The nerve impulse is transmitted from node to node by 
electrotonic spread and the action potentials regenerated at each Node of 
Ranvier; this process is commonly referred to as saltatory conduction. 
In 1928, Ramon y Cayal provided the first description of a teased 
myelinated PNS axon (Fig 1.1). Compact myelin includes the majority of 
the internode. Non-compact myelin provides cytoplasmic continuity 
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between the myelin fonning cell and its vanous reglOns of myelin 
internode. Since the majority of myelin components are synthesized in the 
cytoplasm of myelin-forn1ing cells, cytoplasmic channels at the abaxonal 
surface (not in direct contact with the axon, but in contact with SC 
cytoplasm) are needed to fOlm and maintain the myelin internode. These 
channels contain cytoskeletal components for transport and stability, 
mitochondria for energy and endoplasmic reticulum for local membrane 
biosynthesis. The cytoplasmic channels at the lateral ends of the internode 
(paranodal loops) are major sites of myelin-axon adhesion. The 
membranes of the adaxonal surface are in direct contact with the axons 
and their cytoplasmic channels may transmit axonal signals that regulate 
myelin fonnation, deternlining the length and thickness of the myelin 
internode. Finally, Schmidt-Lantennan incisures cross compact PNS 
myelin and connect outer and inner regions of the internode. These 
structures are more visible in the PNS than in the CNS, and constitute a 
continuous channel of cytoplasm, which extends through the sheath from 
the peri axonal process to the soma. The incisure membrane is 
characterized by the presence of tight junctions that separate paranodes 
and incisures from extracellular space, adherens junctions, that link 
together consecutive layers of the sheath, and gap junctions, that mediate 
diffusion across incisures by fonning a radial pathway for ions and small 
molecules (Balice-Gordon et aI., 1998). 
By Transmission Electron Microscopy (TEM), compact myelin 
appears as a lamellar structure of alternating dark and light lines that spiral 
around the axon. During the process of myelin compaction, both in 
oligodendrocytes and Schwann cells, the cytoplasm is partially excluded. 
Cytoplasm membrane leaflets are closely apposed to fonn the major dense 
lines (MOL), while extracellular leaflets of adjacent lamellae become 
closely apposed to fornl the intraperiod lines (lPL), separated by 2.0 nm in 
the CNS and 2.5 run in the PNS. The spiral membranes of compact myelin 
have a periodicity (distance from dense line to dense line) of 
approximately 13 to 14 run when fixed with aldehydes and embedded in 
epoxy resins (Kirschner and Hollingshead, 1980) and is slightly greater in 
PNS myelin than in CNS myelin. In situ, however, the distances are larger 
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Fig 1.1: Myelin internodes in the peripheral nervous system (PNS). Drawings by Ramon 
Y Cajal of osmic acid fixed (A) and silver impregnated (B) myelinated fibers from the 
PNS. Compact myelin membranes surround the axon (A, in black) and comprise the 
majority of the myelin internode. To illustrate the membrane expansion that occurs 
during myelination, the size of a Schwann cell before myelination (C) is compared to a 
Schwann cell and its "unrolled" myelin internode (D). Cytoplasmjc domains at the outer 
surface of the internode (B, D) are contiguous with the cytoplasmic channels that 
surrounds (paranodes and inner mesaxon) and traverse (Schmjdt-Lantern1an incisures) 
the compact myelin. (Adapted from "Myelin biology and disorders", chapter I , page 4). 
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(17 to 18 nm) when measured by X-ray diffraction (Kirschner and 
Sidman, 1976). 
Since the major function of compact myelin is insulation, it needs 
not to be biochemically complex or molecularly dynamic. In fact, compact 
myelin ultrastructure predicts membrane adhesion as the major function of 
compact myelin molecules. Moreover, adhesion molecules cannot occupy 
large extracellular or cytoplasmic areas and it is more efficient if they have 
a slow turnover rate. Because of its abundance, invariable structure and 
unique biochemical composition, myelin was the first nervous system 
membrane to be isolated and molecularly characterized. Abundant 
proteins in compact myelin include proteolipid protein (PLP) and the 
myelin basic protein (MBP) in CNS compact myelin and PO protein, 
MBP, P2 protein and PMP-22 in the PNS. The different protein content is 
not the only criterion to distinguish between CNS and PNS myelinated 
fibers; in fact, they have a different periodicity and a basal lamina is 
present only around PNS myelinated fibers. In addition, the endoneurial 
space of peripheral nerves is conspicuously abundant and contains 
collagen fibrils, that are not present in the CNS parenchyma. Despite their 
differences, the inner surface of both PNS and CNS myelin internodes are 
separated from the axon by a 12 to 14 nrn periaxonal space and both 
peri axonal spaces contain Myelin Associated Glycoprotein (MAG), 2', 3'-
Cyclic Nucleotide 3'-phosphodiesterase (CNP) and microfilaments (Trapp 
et aI., 1988). 
1.4 Myelin Proteins 
• 1.4.1 Proteolipid protein (PLP) 
PLP is the most abundant CNS myelin protein; it constitutes 
approximately 50% of the total. The gene gives rise to two alternatively 
spliced transcripts that encode the classical PLP protein (a hydrophobic 
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protein with four transmembrane domains and a MW of 26kD) and a 
smaller isoform, named DM20. The only difference between them is the 
presence of an additional 35 aminoacid residues in the intracellular region 
of PLP. The PLP/DM20 gene is expressed primarily by mature 
oligodendrocytes, although small amounts of the proteins have been 
detected in embryonic eNS, PNS, heart, spleen, thymus and lymphnodes 
(Bongarzone et aI., 1999; Bronstein, 2000; Gat"bern et aI., 1997). In 
humans, PLP duplication is a common cause of a dysmyelinating disorder, 
Pelizeaus-Merzbacher disease: affected patients present a range of 
phenotypes, whereby larger duplications or point mutations can result in 
more severe clinical manifestations (Inoue et aI., 1999). Increase of the 
PLP gene dosage in nonmutant mice with only a 2-fold transcriptional 
overexpression results in a dysmyelinating phenotype characteIized by 
severe hypomyelination and astrocytosis, seizures, and premature death. 
This demonstrates that precise control of the PLP gene is a cIitical 
determinant of telminal oligodendrocyte differentiation. Oligodendrocytes 
in the dysmyelinated eNS express a range of genes typical of mature cells, 
yet are unable to assemble sufficient myelin. Oligodendrocytes contain 
abnormal vacuoles and stain intensely for PLP and other proteins such as 
MAG. The findings suggest that with high gene dosage much of the PLP, 
and possibly other proteins, is missorted and degraded in the lysosomal 
system. SurpIisingly, mutant mice that lack expression of a targeted PLP 
gene fail to exhibit the dysmyelinated phenotype (Boison and Stoffel, 
1994). Oligodendrocytes are still competent to myelinate eNS axons of all 
calibers and to assemble compacted myelin sheaths. Ultrastructurally, 
however, the electron-dense 'intraperiod' lines in myelin remain 
condensed, correlating with its reduced physical stability. This suggests 
that after myelin compaction, PLP forms a stabilizing membrane junction, 
similar to a "zipper." Animal models of PMD, the jimpy and the msd 
spontaneous mutant mice, accumulate PIp gene products in the perinuclear 
region, are unable to transport them to the cell surface and undergo a two-
to threefold increase in oligodendrocyte cell death (Gow et aI., 1998). 
Recently, transgenic mice expressing only the DM-20 isoform were 
created. Although DM-20 is incorporated into functional compact myelin 
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sheaths in young animals, the analysis of these mice revealed that the 35 
amino acid PLP-specific peptide is required to engender the normal 
myelin period and to confer long-term stability on this multilamellar 
membrane (Stecca et at, 2000). As already mentioned above, both PLP 
and DM20 are expressed in the PNS. The role of the two molecules within 
the PNS has not been clarified yet, but it is known that several PLP 
mutations (null- and point mutations) have been identified in different 
patients affected by peripheral neuropathies (Shy et aI., 2003). 
• 1.4.2 Myelin basic protein (MBP) 
MBP accounts for approximately 35% of total protein in eNS 
myelin and 15% in PNS myelin. It has been found in all vertebrates that 
have myelin, both in the eNS and in the PNS. It is localized at the 
cytoplasmic surface of both central and peripheral compact myelin. It 
belongs to a family of alternatively spliced, highly positively charged 
extrinsic membrane proteins (Zeller et aI., 1984), which bind negatively 
charged lipids. It is localized in the major dense line of myelin and in eNS 
it is required for normal myelin compaction. The MBP-deficient shiverer 
mice, natural mouse mutants carrying a deletion of the 3' end of the 
myelin basic protein gene, which completely prevents production of 
mature mRNA and protein, show a severe hypomyelination, a 
delamination in the eNS major dense line, tremors and tonic seizures 
(Molineaux et aI., 1986). Although MBP is also expressed in the PNS, 
examination by electron microscopy showed that the peripheral nervous 
system in the shiverer mice, in contrast to the markedly abnormal central 
nervous system, is grossly normal. Myelin sheaths are of the usual 
thickness and exhibit normal periodic structure consisting of alternating 
major dense and intermediate lines. Subtle abnorn1alities do occur, 
however, consisting of increased numbers of Schmidt-Lanterman 
incisures, abelTant terminations of myelin lamellae in internodal regions, 
invagination of the axon by the inner tongue of the myelin sheath, myelin 
debris in both axon and Schwann cells, and disruption of outer myelin 
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Fig 1.2 Topographical models ofPLP and DM-20 in a membrane bilayer. Four 
transmembrane domains, a-d, are depicted for both proteins, in which numbers represent 
the amino acids in the vicini ty of the membrane surfaces. In thjs model, the amino acids 
K150 of PLP and KIlO of DM-20 define the beginning of the third transmembrane 
domain for each protein (Hartmann et aI. , 1989). Note that F151 in PLP is at the bilayer 
surface but that F116 in DM-20 is displaced toward the center of the membrane by the 
fi ve amino acids, Gly-Leu-Ser-Ala-Thr. This displacement could increase the size of the 
second extracellular domain. (Adapted from Stecca at aI. , 2000). 
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lamellae (Rosenbluth, 1980; Gould et al., 1995). Despite the absence of 
myelin basic protein, the peripheral manifestations of this gene are 
relatively minor and probably not severe enough to compromise peripheral 
nerve function significantly, suggesting the presence of another myelin 
gene in PNS that can rescue MBP absence (Martini et al., 1995). 
• 1.4.3 P2 protein 
P2 protein is an extrinsic membrane protein that is enriched in 
compact PNS myelin where it can participate in fusion of the major dense 
line. P2 was also detected immunocytochemically and biochemically in 
rabbit central nervous system (CNS) myelin. In the PNS, P2 protein was 
detected immunocytochemically and biochemically in rabbit sciatic nerve 
myelin. Immunocytochemically, P2 antiserum only stained a p0l1ion of 
the myelin sheaths present. The myelin sheaths not reacting with P2 
antiserum had small diameters and represented less than 10% of the total 
myelinated fibers (Trapp et al., 1983). 
The species differences in the expression of P2 are also confirmed by the 
differential potentials of the protein to induce an autoimmune 
demyelinating disease both in PNS and CNS. In fact, in inbred Lewis rats, 
P2 basic protein from bovine PNS myelin produced experimental allergic 
neuritis (EAN) without involvement of the brain or spinal cord. In guinea-
pigs, bovine P2 did not produce EAN but large doses produced mild 
experimental allergic encephalomyelitis (EAE). In rabbits, bovine P2 
produced both mild EAE and EAN. Finally, P2 protein shares significant 
homology with cellular retinoic acid binding protein (CRABP), and 
cellular retinol binding protein (CRBP), a family of proteins that have 
lipid binding activities and function in fatty acid transport (Uyemura et al., 
1984). 
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• 1.4.4 Peripheral mvelin protein 22 (PJovfP22) 
It is a minor, but crucial component of the myelin sheath of 
peripheral nerves. It represents approximately 2-5% of total myelin in 
PNS. PMP22 belongs to a family of membrane proteins that is 
characterized by four hydrophobic domains and conserved amino acid 
motifs. The group includes epithelial membrane protein-l (EMP-l), EMP-
2, and EMP-3 (Jetten and Suter, 2000). PMP22 is widely expressed in 
neural and non-neural tissues, during embryonic life and in the adult 
(Baechner et aI, 1995). PMP22 is most highly expressed by myelinating 
Schwann cells and its highest levels of expression were associated with 
late stages of myelination; however the presence of the protein in 
nonmyelinating SCs and in SCs commencing myelination supports 
multiple roles for PMP22 in peripheral nerve biology (Notterpek et aI, 
1999). Detailed immunohistochemical analyses have localized PMP22 to 
the plasma membrane of non-myelinating and myelinating Schwann cells 
as well as to the compact portion of myelin (Haney et aI., 1996; Snipes et 
aI., 1992). PMP22 is also found in the CNS, but at much lower levels than 
in peripheral nerves (Parmantier et al., 1995). Its transcripts have been 
found also during mouse CNS development (Parmantier et al., 1997). In 
the adult, PMP22 mRNA levels are approximately lO-fold higher in 
sciatic nerve, compared to the lung and intestine, and about 50 to 100-fold 
higher than in brain. Studies conducted in primary rat SC cultures showed 
that the PMP22 gene is regulated by two alternative promoters that are 
located immediately upstream of two alternative 5' noncoding exons 
(exons lA and IB). While both transcripts are coexpressed in tissues and 
cell lines, the transcripts containing exon IA are preferentially expressed 
in myelinating Schwann cells, while transcripts containing exon 1 Bare 
preferentially expressed in tissues that do not form peripheral myelin 
(Suter et al., 1994). PMP22 encodes a hydrophobic integral membrane 
protein of 160 amino acids, with a predicted non-glycosylated molecular 
weight of approximately 18kD. Given the fact that the protein is not 
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purified yet, computational analysis of these hydrophobic domains 
suggested four potential transmembrane domains. These putative 
intracellular domains are small and unlikely to be involved in specific 
interactions with intracellular proteins. On the other hand, the extracellular 
loops of PMP22 may directly interact with other molecules, but so far no 
such extracellular interaction has been shown, although direct association 
of PMP22 with PO in myelin membrane has been highlighted by co-
immunoprecipitation experiments (O'Urso et aI., 1999). Interestingly, 
PMP22 protein has been found to be glycosylated. Human and cat PMP22 
carry the HNK-l carbohydrate epitope, previously found on other cell 
surface glycoproteins, including PO and many other proteins involved in 
cell-cell and cell-extracellular matrix adhesion (Hammer et aI., 1993). 
While PO is well characterized as a major adhesion molecule in PNS 
myelin (see chapter 1.5), the function of PMP22 is still unknown; it might 
be involved in regulating cell proliferation, death, differentiation and 
adhesive processes (Quarles 2002), although strong homophilic 
interactions have been excluded (Takeda et aI., 2001). Most of what is 
known about the crucial function of PMP22 in proper development and 
maintenance of the nervous system has been learned from genetics, since 
PMP22 is the culprit gene in the most common fOlm of hereditary motor 
and sensory neuropathies (HMSN) in human and rodents (Naef and Suter, 
1998). This critical role of PMP22 in peripheral nerves became clear after 
the mouse PMP22 gene was mapped on chromosome 11, a chromosomal 
segment that is syntenic to human chromosome 17p 11.2 (Suter et aI, 
1992a, 1992b). This human chromosomal region had been previously 
linked to the most common form of HMSN, called CMTIA (see chapter 
1.8). FUl1hermore, the importance of PMP22 in PNS was also supported 
by the findings that the mouse mutants Trembler (Tr) and Trembler-J (Tr-
J), natural mouse mutants recognized as potential animal models for 
severe forms of HMSN, Dejerine-Sottas Syndrome (OSS), carry point 
mutations in hydrophobic regions of the PMP22 protein (Suter et aI., 
1992a, 1992b, 1993). Finally, it has been recently showed, in a novel 
pmp22 knock-out mouse line, generated by replacing the first two coding 
exons with the lacZ reporter, that PMP22 can bind the integrinllaminin 
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complex, mediating the interaction of SCs with the extracellular 
environment. These PMP22-deficient mice present peripheral nerves that 
display the characteristics of tomaculous neuropathy. In the absence of 
PMP22, myelination of peripheral nerves is delayed, and numerous axon-
SC profiles show loose basal lamina. PMP22 and P4 integrin are 
coexpressed at the cell surface and can be coimmunoprecipitated together 
with laminin and a6 integrin (Amici et aI., 2006). 
• 1.4.5 Mvelin Associated Glycoprotein (MAG) 
MAG is a minor myelin constituent, comprising approximately 1 % 
and 0.1 % of total myelin proteins in CNS and PNS respectively. It is a 
glycoprotein of the Ig-superfamily, with a high homology to N-CAM. 
Two distinct isofonns, large MAG (L-MAG) and small MAG (S-MAG), 
are produced through the alternative splicing of the ptimary MAG 
transcript and differ in their cytoplasmic domain. L-MAG is necessary for 
CNS myelin integrity, while S-MAG is sufficient to maintain PNS 
integrity (Fujita et aI, 1998). To elucidate the role of MAG in the axon-
Schwann cell interaction leading to myelination, neonatal rodent Schwann 
cells were infected in vitro with a recombinant retrovirus expressing MAG 
antisense RNA. A proportion of the Schwann cells infected with the MAG 
antisense virus did not myelinate axons and expressed lower levels of 
MAG than control myelinating Schwann cells, as measured by 
immunofluorescence. Electron microscopy revealed that the affected cells 
failed to segregate large axons and initiate a myelin spiral despite having 
fonned a basal lamina, which nonnally triggers Schwann cell 
differentiation. Taken together these observations strongly suggested that 
MAG was the critical Schwann cell component induced by neuronal 
interaction that initiates peripheral myelination (Owens and Bunge, 1991). 
Conversely, experimentally increased levels of MAG in SCs accelerated 
initial ensheathment of dorsal root ganglia (DRG) neurites Owens et aI., 
1990). However, MAG-deficient mice have been produced; they appeared 
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nonnal in motor coordination and spatial learning tasks. Normal myelin 
structure and nerve conduction in the PNS was observed, with N-CAM 
overexpression at sites nonnally expressing MAG, indicating a possible 
compensatory effect. On the other hand, in the CNS the onset of 
myelination was delayed, and subtle morphological abnonnalities were 
detected indicating that MAG participates in the formation of the 
periaxonal cytoplasmic collar of oligodendrocytes and in the recognition 
between oligodendrocyte processes and axons (Montag et aI., 1994). The 
analysis of adult and aged MAG -1- mice revealed degenerative alterations 
of myelin in the PNS, with the forn1ation of classical onion bulbs; the 
presence of such alterations suggest an in vivo role for MAG in the 
maintenance of peripheral myelin integrity. Mutant mice expressing only 
one of the two isofonns alternatively showed a differential role of the L-
MAG isofonn in CNS and PNS myelin. 
1.5 Myelin Protein Zero 
Protein zero is the major protein in myelin of the peripheral 
nervous system (PNS), where it constitutes 50 to 60% of total protein 
content in peripheral myelin. It was discovered and characterized more 
than 30 years ago. The human protein is a member of the immunoglobulin 
gene superfamily; it is a -30 kD integral membrane protein, constituted by 
a single disulfide-stabilized VH-like domain, a single transmembrane 
domain, one glycosylation site and relatively few other post-translational 
modifications. It contributes to peripheral myelin structure across a wide 
phylogenetic range that includes mammals, reptiles, birds and amphibian; 
only in fish, it is abundant also in the CNS (Schweitzer et aI., 2003). 
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aranodal loops 
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Fig. 1.3: Upper panel: Schematic longitudinal section through a single myelinated axon 
showing the distribution of some of the peripheral nerve myelin proteins, MAG, Po, 
PMP22, P2, MBPs and Cx32 and their association with the major domains of compact 
and noncompact myelin. Lower panel: Schematic diagram of the putative topology and 
orientation of the major myelin proteins with respect to the Schwann cell plasmalemma 
(modified fi'om Suter et a!. 1993). 
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• 1.5.1 PO eDNA 
PO has been cloned so far from human (Hayasaka et aI., 1991), rat 
(Lemke and Axel, 1985), mouse (Lemke et aI., 1988; You et aI., 1991), 
chicken (Barbu, 1990), shark (Saavedra et aI., 1989), trout (Stratmann et 
aI., 1995) and zebrafish (Schweitzer et aI., 2003) (Fig. 1.4). Its cDNA is 
1.85 kb long: it includes a coding sequence of 744 nucleotides and a long 
3' untranslated region. It encodes a single RNA species of 1.9kb. A 29-
residue signal peptide, a 124-residue extracellular domain, a 26-residue 
transmembrane domain and a 69-residue intracellular domain were first 
predicted, then confirmed by direct sequencing of the bovine protein 
(Sakamoto et aI., 1987). The structure of the different domains was then 
studied: the extracellular domain contains an immunoglobulin-like fold; it 
is stabilized by a single disulfide bond between Cys21 and Cys98 and it 
includes an N-glycosylation on Asn93. The 69-residue intracellular 
domain contains several Arg and Lys residues and, therefore, it is highly 
basic. 
• 1.5.2 Mpz gene 
The gene codifying for PO glycoprotein was first isolated and 
characterized in rat and mouse. It is relatively small (7kb), consisting of 6 
exons (Lemke et aI., 1988; You et aI., 1991). Careful analysis of gene and 
protein structure revealed that the separation of the different domains 
mirrors the exon segregation; in fact, exon I codifies for the 5' 
untranslated region of the mRNA and for the major part of the protein 
signal peptide (from residue -29 to residue -7); both exon 2 and 3 code for 
the remaining part of the signal peptide and for the extracellular domain 
(from residue -6 to residue 120); ex on 4 includes the DNA region giving 
rise to the transmembrane domain (from residue 121 to residue 165) and, 
finally, exon 5 and 6 codify the PO cytoplasmic domain and the 3' 
untranslated region (Lemke et at, 1988). Despite its difference in length 
with rodent Mpz gene, human A1PZ preserves its genomic organization, 
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Fig 1.4: Structural homologies between PO molecules of different vertebrate species. The 
deduced amino acid sequence of zebrafish PO is aligned with trout LP 1, as well as shark, 
human, rat, mouse, bovine, Xenopus and chicken PO. The sequence boundaries 
corresponding to exons I to VI of the human PO gene are indicated. The extracellular, 
transmembrane and cytoplasmic domains are indicated by the horizontal bands of green, 
yellow and pink respectively.The multiple species alignment for the nine different species 
reveals the extent of homology: lOO%, white letters on red field, >50%, red letters. 
(Adapted from Myelin Biology and Disorders, chapter 20, Kirschner, Wrabetz and Feltri, 
figure 20.1). 
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with six exons and conservation between exonic and promoter sequences 
(Pham-Dinh et aI., 1993). The chromosomal location is conserved for both 
the mouse Mpz and the human MPZ (being on chromosome 1 Hayasaka et 
aI., 1993; Kuhn et aI., 1990; You et aI., 1991), whereas rat Mpz is located 
on chromosome 13 (Liehr et aI., 1995). 
• 1.5.3 Mpz gene expression 
Mpz expression is mainly limited to the Schwaan cell lineage. In 
addition to that, the otic placode, vesicle, notochord, enteric neural crest 
and olfactory ensheathing cells express the J.,1pz mRNA. Mpz mRNA and 
protein expression is basal before birth and increases during early 
postnatal life, coincident with the onset of myelination (Lee et aI., 1997). 
Mpz mRNA appears first in a subset of neural crest cells and is maintained 
in Schwann cell precursors and embryonic Schwann cells (Baron et aI., 
1994; Zhang et aI., 1995). Protein expression has been detected in the 
neural crest of chicken (Bhattacharyya et aI., 1991) and on the surface of 
freshly cultured cells from E 14.5 rat nerve (Lee et aI., 1997). 
Postnatal expression of PO mRNA increases and distinguishes the 
differentiation of non myelin-fOlming from myelin-forming Schwann 
cells: levels are undetectable in the former, whereas they are strongly 
induced in the latter. The fate choice between the two different cell types 
and the levels of Mpz expression are determined by their contact with 
axons. In fact, myelinating Schwann cells require contact with axons for 
both the induction and the maintenance of high-level Mpz expression 
(Lemke and Chao, 1988; Gupta et aI., 1988; Trapp et aI., 1988). The 
inductive axon signals include increased intracellular levels of cAMP and 
brain-derived neurotrophic factor (BDNF). On the other hand, various 
agents have been identified, that are able to repress .Mpz expression in 
Schwann cells: SV 40 T -antigen with c-Jun (Bharucha et aI., 1994), c-jun 
on its own (Parkinson et aI., 2004), serum, GGF, TGF betas, bFGF2 
(Cheng and Mudge, 1996; Fernandez-Valle et aI., 1993; Mews and Meyer, 
1993; Morgan et aI., 1991; 1994) and NT3 (Cosgaya et aI., 2002). Some of 
25 
these may be responsible for maintainance of low levels of Mpz 
expression in premyelinating Schwann cells and during differentiation of 
non myelin-forming Schwann cells. 
• 1.5.4 Mrz gene expression regulation 
A quantitative analysis in the rat sciatic nerve of myelin protein gene 
expression during development (Stahl et aI., 1990), revealed that Afpz 
expression is thought to be primarily transcriptionally regulated; in fact, 
Mpz mRNA appears immediately before PO glycoprotein and is 
remarkably upregulated during myelination. 
After the genomic structure of Mpz was revealed, a promoter 
region, without a canonical TAT AA box was identified; a 1.1 kb region 
was in fact capable of driving expression of a reporter gene specifically 
only in transfected Schwann cells, and not in other cell types. Using the 
same 1.1 kb promoter region, activated expression of different proteins 
was specifically achieved in Schwann cells of transgenic mice (Messing et 
aI., 1992). Nevertheless, levels oftrangene expression were not consistent, 
indicating that the 1.1 kb of proximal Mpz promoter were sufficient to 
activate appropriate Schwann cell-specific expression, but not enough to 
achieve full amplitude of Mpz expression. Further studies conducted on 
cultured Schwann cells allowed the dissection of different cis-acting 
elements within the 1.1 kb Mpz promoter (Brown and Lemke 1997). 
Transcription factors like Spl and NF-Y are bound to different DNA 
sequences in the proximal 350 nucleotides, but the basis for cell-specific 
activation remains unclear. Moreover, several other transcription factors 
are upstream regulators of Mpz in developing nerve, including Oct6, 
Krox20 and Sox 10. Oct6 strongly represses the Mpz promoter in vitro 
(Monuki et aI., 1989), but functions as an activator in vivo (Belmingham 
et aI., 1996; Jaegle et aI., 1996). Krox20 is necessary in vivo for terminal 
differentiation of myelin-forming Schwann cells (Topilko et aI., 1994), as 
Krox20-null mice produce none of the normal up-regulation of }'4pz 
expression in post-natal nerve. Finally, the transcription factor Sox 10, 
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which is required for fonnation of Schwann cells (Britsch et aI., 2001), is 
expressed at all stages of Schwann cell life and is able to upregulate both 
endogenous Mpz expression and the Mpz promoter, when ectopically 
expressed in N2A neuroblastoma cell lines (Peirano et aI., 2000). Whether 
this regulation is direct remains unclear for all three. 
In order to produce levels of mRNA and protein expression of 
exogenous genes, comparable to endogenous Mpz, with a correct 
topographical and temporal pattem, insertions into exon I of an Mpz-
based transgene, containing 6kb of 5' flanking region and 400 nucleotides 
of 3' region were generated (Feltri et aI., 1999, Previtali et aI., 2000; 
Wrabetz et aI., 2000; Yin et aI., 2000). Recently, a highly conserved 
element within the first intron of the Mpz gene has been identified, which 
contains binding sites for the early growth response 2 (Egr2/Krox20) 
transcription factor. Egr2 can act synergistically with SoxlO to activate 
this intron element and to induce Mpz expression to the high levels found 
in myelinating Schwann cells (LeBlanc et aI., 2006). 
• 1.5.5 PO glvcorrotein svnthesis 
Like the proteins of other plasma membranes, PO synthesis is 
localized to the endoplasmic reticulum, then processed through the Golgi 
network and transported intracellularly in membrane vescicles that finally 
fuse with the polarized plasma membranes of Schwann cells (Mellman 
and Warren, 2000; Eichberg et aI, 2002). Microtubule disassembly 
experiments, associated with confocal microscopy and electron 
microscopic immunocytochemistry, showed that microtubules are 
necessary for specific myelin protein transport; in fact, following 
colchicine-mediated microtubule disassembly, PO, MAG and laminin 
accumulated in Schwann cell perinuclear cytoplasm (Trapp et aI., 1995). 
However, the process through which PO and MAG reach their final 
location within the SC plasma membrane seems to be independent of 
microtubules and most likely occurs by ligand receptor binding 
mechanisms, between carrier vesicles and target membrane. Like other 
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myelin proteins, PO possesses targeting sequences that act in polarized 
cells; in fact, transfection of PO glycoprotein in non-polarized HeLa cells 
produce surface membrane polarization, through PO mediated homophilic 
adhesion. In addition, PO glycoprotein has been stably transfected into 
other cell types, for instance, Madin-Darby canine kidney (MDCK) cells. 
MDCK cells are ideal for this purpose because they are an easily 
transfected cell line that polarizes into two membrane domains. In MDCK 
transfected cells, PO is targeted to the basolateral surface. When the same 
cells are transfected with a deleted form of PO, lacking its cytoplasmic 
domain, the intracellular localization of PO changes to the apical surface 
(Kidd et aI., 2006). 
Post-translational modifications of PO occur both in the 
extracellular and intracellular domain; the extracellular region undergoes 
disulfide bond formation between Cys21 and Cys98 (Shapiro et aI., 1996), 
glycosylation of Asn93 with a complex carbohydrate (Gallego et aI., 2001; 
Poduslo, 1990) and sulfation of the N-acetylglucosamine residues of the 
carbohydrate. In the cytoplasmic domain, the post-translational 
modifications include acylation of Cys 153 with palmitic acid (Bizzozero 
et aI., 1994) and phosphorylation of Tyr 191, Ser 181 and Ser204 (Eichberg 
et aI, 2002; Hilmi et aI., 1995; Iyer et aI., 1996). Of particular interest for 
the topic of this thesis is the fact that in physiological conditions, cleavage 
of PO can occur at the level of its cytoplasmic domain, generating a 
truncated glycoprotein of approximately 25kD (Agrawal et aI., 1990): this 
shorter protein has been isolated and characterized in bovine; it is 
truncated at the level of residue Q215 (numbering of residues 
comprehensive of 29-residue signal peptide) (Qualtieri et aI., 2006). 
• 1.5.6 PO glycoprotein (unction 
The hypothesis that PO glycoprotein was a transmembrane protein 
responsible for interactions at both the cytoplasmic and extracellular 
appositions in PNS myelin originated from application of x-ray diffraction 
techniques to study myelin membrane packing in sciatic nerves from 
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nonnal mice and the shiverer mouse mutant (Kirschner & Ganser, 1980). 
The shiverer mouse has an extensive deletion in the gene encoding MBP; 
as a result, the mutant is not able to express functional MBP mRNA or 
protein. In the eNS, this mutation results in a severe hypomyelinated 
phenotype, whereas in the PNS the myelin appears nonnal. This finding, 
together with the fact that PO is the most abundant protein in PNS myelin, 
supPOlied the conclusion that PO protein specifically accounts for spacing 
and adhesion at both Schwann cell membrane surfaces. Several different 
functional studies, conducted in vitro on various transfectcd cell lines or 
myelinating cultures, and in vivo on transgenic mice sUPPOlied this role of 
PO in promoting peripheral myelin membrane adhesion and compaction 
through homophilic interactions. First of all, cells transfected with PO 
acquire the ability to adhere to each other, while anti-PO antibodies inhibit 
the adhesion (O'Urso et al., 1990; Filbin et al., 1990; Schneider-Schaulies 
et aI., 1990). Then, the cytoplasmic domain of PO is required for 
extracellular adhesion to occur: its truncation (at the level of the last 52 or 
59 residues) inhibits adhesion of full-length PO by a dominant negative 
mechanism (Wong and Filbin, 1994, 1996). Finally, the use of transfected 
cell lines helped also in identifying the possible role of post-translational 
modifications for PO adhesive function. In fact, glycosylation at Asn93 
with complex carbohydrate (Filbin and Tennekoon, 1991, 1993), disulfide 
bond formation (Zhang and Filbin, 1994) and possibly acylation (Gao et 
aI., 2000) all apparently modulate PO adhesive function. Moreover, 
antibodies against the HNKI carbohydrate chain, expressed by PO at its 
single N-glycosy1ation site, partially inhibit PO homophilic interaction 
(Griffith et aI., 1992). In vitro and in vivo myelination experiments further 
confinn the role of PO in adhesive homophilic interaction and fonnation of 
the intraperiod line: first, Schwann cells infected with a retrovirus coding 
for PO antisense RNA show diminished levels of PO protein and are unable 
to myelinate, or fonn myelin with uncompacted lamellae when co-coltured 
with DRG neurons (Owens and Boyd, 1991). Second, mice lacking PO 
glycoprotein (PO-/- mice) are able to fonn a multilamellar spiral structure 
around larger axons. This structure is uncompacted and therefore results in 
reduced nerve conduction velocities. In addition, in PO -/- mice intraperiod 
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lines are absent. Finally, some myelin sheaths show compaction, 
particularly at the major dense line, suggesting that other molecules can 
compensate for the loss of PO (Giese et aI., 1992). The mechanism through 
which PO-mediated homophilic interaction occurs was clarified by the X-
ray resolution of PO extracellular domain structure: in the myelin sheath, 
PO forms tetramers in the plane of the membrane; these tetramers can 
interact with other tetramers on the opposing cell membrane. The 
tetrameric assembly of PO proteins is supported by analytical 
ultracentifugation data showing that oligomerization of the extracellular 
domains of the rat recombinant protein is energetically favorable in 
solution (Shapiro et aI., 1996, Inouye et aI., 1999 - Fig 1.5). 
• 1.5.7 PO cvtoplasmic tail {imction 
Electron microscopy and membrane diffraction studies helped to 
clarify the cytoplasmic apposition between Schwann cell plasma 
membranes in compact myelin. It is in fact commonly thought that the 
formation of the so-called Major Dense Line, is due to electrostatic 
interactions between the basic cytoplasmic domain of PO and the acidic 
phospholipids present in SC plasma membrane; this hypothesis is 
supported by the fact that a peptide containing 65 of the 69 residues of the 
intracellular domain of PO is able to bind to and to aggregate artificial 
phospholipid vesicles (Ding and Brunden, 1994). However, this 
hypothesis is strongly questioned by the evidence that even ifpH and ionic 
strength vary, the Major Dense Line remains unchanged. As a 
consequence, it has been proposed that the cytoplasmic apposition is likely 
to result from lipid anchoring and hydrophobic interactions between PO 
intracellular domains (Inouye et aI., 1999). Furthermore, evidence from PO 
and MBP knock-out animals seems to indicate that PO is not the only 
molecule responsible for Major Dense Line compaction: in fact, in mice 
lacking both molecules axons are enwrapped by myelin-like processes 
devoid of the major dense line, while mice deficient in either protein 
showed partial and normal compaction (Martini et aI., 1995). 
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In addition to that, PO, like other adhesion receptors, could also 
have a signal transduction role; this hypothesis is supported by the finding 
of phosphorylation of setine and tyrosine residues in the cytoplasmic 
domain (Brunden and Poduslo, 1987; Hilmi et aI., 1995; Iyer et aI., 1996). 
Other evidences for this role of PO glycoprotein comes from transfection 
experiments in HeLa cells, which indicate that PO can control aspects of 
Schwann cell differentiation, such as polarization and gene expression: in 
fact, HeLa cells expressing PO ectopically can augment the adhesion 
program in the cells, by the placement of junctional proteins at cell-cell 
contacts, promoting the assembly of desmosomes and adherens junctions 
and suppressing the transfom1ed phenotype to an epithelioid phenotype; 
this response is paralleled by an increase in expression levels for proteins 
that are nOffi1ally associated with epithelial junctions (Le. N-cadherin, a-
catenin, and vinculin; Doyle et aI., 1995). Furthermore, when PO is 
introduced in HeLa cells, the carcinoma cell line regains adhesion-
mediated growth control, together with the acquisition of contact 
inhibition and loss of anchorage-independent growth. Finally, PO-
expressing HeLa cells lose their tumorigenic and metastatic potency when 
injected into nude mice. Other findings supporting the potential signal 
transduction role for PO atise from in vivo studies conducted on 
engineered mice: in PO null mice myelin gene expression is altered and 
MAG, E-cadherin and beta-catenin are mislocalized. 
Given the fact that PO could signal to regulate Schwann cell 
polarization, junction fOffi1ation and gene expression during myelination, 
recent disease-related evidence further suggests that the cytoplasmic 
domain of PO may signal to the extracellular domain, regulating its own 
adhesiveness. Serine residues in the cytoplasmic domain of PO are 
phosphorylated by Protein Kinase C (PKC). When the PKC target motif 
(RSTK motif) or an adjacent setine residue is mutated, PO adhesive 
function is abolished and peripheral neuropathy can develop in humans. 
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Fig. 1.5: Molecular structure of PO extracellular domain and its tetrameric arrangement. 
The molecule is represented by its backbone and the disulfide bonds are indjcated in 
yellow. A) The tetramer (formed of 4 PO molecules) is viewed looking down onto the 
membrane surface. B) The tetramer is viewed perpendicular to that in A), parallel to the 
membrane surface. C) Lateral view, parallel to the membrane surfaces, of two PO 
glycoproteins forming the adhesive interface. D) View of the head-to-head interface, 
early event in myelin formation (Adapted from Shapiro et aI1996). 
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Consistent with these data, PKC alpha together with the PKC 
binding protein RACK-l and p65 adaptor protein are immuno-precipitated 
with PO; moreover, inhibition of PKC activities abolishes PO-mediated 
adhesion in an in vitro system (Xu et aI., 2001, Gaboreanu et aI., 2007). 
Finally, the role of tyrosine phosphorylation remains to be detennined. 
Tyrosine phosphorylation occurs mainly at residue Tyr191 (Iyer et aI., 
2000; Xu et aI., 2000); however, mutations at this site do not influence PO 
adhesiveness (Xu et aI., 2001). 
In summary, the cytoplasmic tail of PO has several hypothetical 
functions in trafficking, Major Dense Line compaction, extracellular 
domain adhesiveness and intracellular signaling. All these different 
functions may have important implication for the pathogenesis of CMT 1 b 
neuropathy (see chapter 1.8). 
• 1.5.8 PO prenata16mction 
As already discussed in this chapter, PO mRNA and protein are 
expressed at low levels expression during pre-natal life in a subpopulation 
of neural crest cells and in Schwann cell precursors (Baron, 1994; 
Bhattacharyya, 1991; Lee, 1997); the presence of PO mRNA is also found 
in the otic placode, enteric nervous system and olfactory ensheathing cells 
(Lee et aI., 2001). Such a widespread prenatal expression indicates 
possible additional functions of PO, outside the myelin sheath. One 
possibility is that PO mediates heterophilic adhesion to neurites: in fact, 
cells expressing ectopic PO are able to promote neurite outgrowth in dorsal 
root ganglion neurons with neurites of a mean length of about 150 
microns. (Schyneider-Schaulies, 1990). In addition, several observations 
predict a possible role for PO in the maintenance ofaxons. First, both 
heterozygous and homozygous PO null mice develop axonal degeneration 
(Frei et aI., 1999; Giese et aI., 1992; Martini et aI., 1995/2). Second, 
several PO mutations in patients cause the axonal fonn of Charcot-Marie-
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Tooth, with minimal myelin involvement, pupillary signs and deafness 
(De Jonghe et aI., 1999; Marrosu et aI., 1998). 
1.6 PNS Development 
Different components of the PNS originate from different germ 
layers. The neuroectoderm gives rise to neurons and glial cells, while the 
nerve sheath and nerve vasculature derive from the mesoderm. The cells 
that differentiate into neurons and glial cells in the trunk region are the 
neural crest cells. During embryonic development, neural crest cells are 
formed at the border between the neural plate and the presumptive 
epidermis, overlaying the lateral plate mesoderm in a gastrulating embryo. 
Two processes determine neural crest cell development: 
delamination and fate determination. 
The process of neural crest delamination is important for 
differentiation and migration of these cells towards target organs. As a 
first step, the cells must switch from an epithelial to a mesenchymal 
morphology. The zinc-finger protein Slug is considered a good marker for 
neural crest cell induction and subsequent delamination in Xenopus, 
chicken and mouse embryos, even if its involvement in neural crest 
induction and delamination remain unclear; in fact its deletion does not 
cause any failure in this process (Jiang et aI., 1998). Delamination of 
neural crest cells starts at the rostral end of the embryo in Slug positive 
migrating cells. It was also demonstrated that ectopic expression of 
Noggin, a BMP-4 inhibitor, can prevent migration and positively regulate 
the epithelial-mesenchymal transition (Sela-Donenfeld et aI., 1999). 
Neural crest, originating from rostral to caudal levels, can generate 
distinct but also overlapping sets of derivatives (Baker et al., 1997). In 
order to demonstrate this hypothesis, a series of homotypic graft 
experiments were performed; these experiments helped to demonstrate for 
example that only a small population of trunk neural crest generate 
chromaffin cells of the adrenal, while SC derive from neural crest cells of 
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the entire antero-postelior axis (Le Douarin et al., 1993). FUl1hermore, 
several tracing experiments were perfOlmed to understand if the fate 
decision of neural crest cells is due to an instructive action of the 
environment on a homogeneous population of cells or to a selective action 
on a collection of committed cells. The results of these studies show that 
while most pre-migratory cells, such as sensory neurons and glia, are 
multi potent, there are also precursors generating a single unique neural 
crest derivative (Frank and' Sanes, 1991). Rat and mouse neural crest cells 
were grown at clonal density, in order to understand their entire repe110ire: 
the results indicate that many cells, before leaving the neural crest, are 
multipotent self-renewing stem-like cells (Ito et al., 1993). Using these 
clonal cell culture techniques, several factors that are potentially involved 
in the lineage determination of the neural crest were identified. One of 
these factors is GGF-2. This is the product of the neuregulin gene and it 
can induce differentiation of neural crest cells into SCs (Shah et al., 1994). 
On the contrary, BMP-4 or BMP-2 promote neuronal differentiation, 
while smooth muscle cells are induced by TGFj3 (Shah et aI., 1996). 
• 1.6.1 Schwann Cell development 
As already introduced in the preVIOUS paragraph, dUling 
development, SCs originate from a multipotent migratory cell population 
that derives from the neural crest. 
The process of SC development involves three transitions: 
1- from neural crest cells to precursor SCs; 
2- from precursor to immature SCs; 
3- from immature to the myelinating and the non myelinating SCs (Fig 
1.6). 
Only the first and the last of this transition points involve a fate choice 
decision. The regulation of gliogenesis from the neural crest is not clear 
yet; some future glial cells already enter the glial lineage at the onset of 
crest migration, while other cells start glial development later. The signals 
important for inducing glial development from both early and late entry 
35 
crest cells still need to be clarified. In vitro and in vivo experiments 
identified two growth factor signals that are involved in regulating early 
SC development in embryonic nerves: p neuregulin 1 and endothelin 
(Brennan et aI., 2000; Garratt et aI., 2000). Very likely these factors have a 
role in the establishment of the PNS glial lineage. Neuregulin in fact 
strongly suppresses neuronal differentiation of rat neural crest stem cells 
while promoting or allowing glial differentiation. (Shah et aI., 1994). In 
addition, p neuregulin 1 is required for some aspects of neural crest 
migration: in fact the blockade of the neuregulin signalling pathway 
results in inefficient development of the sympathetic ganglia, due probably 
to the failure of sympathogenic neural crest cells to migrate to the 
appropriate site (Garratt et aI., 2000). 
One key regulator of PNS glial differentiation is the transcription 
factor Sox-l 0, which is initially expressed in the earliest migrating neural 
crest cells. Interestingly, mice that carry a spontaneous or a targeted 
mutation of Sox 1 0 show neuronal cells in dorsal root ganglia, but no 
Schwann cells or satellite cells (Britsch et aI., 2001). Therefore, it is very 
likely Sox 10 has a major function in undifferentiated crest cells, to drive 
their choice between neuronal and glial development. In this light, it is 
interesting to know that ErbB3 gene expression in neural crest cells is 
under SoxlO control. ErbB3 gene product is a neuregulin receptor: in fact, 
as observed in SoxlO mutant mice, the down-regulation of ErbB3 receptor 
is one of the causes of several changes in development of neural crest 
cells. 
• 1.6.2 Neural crest - SC precursor transition 
As already mentioned above, one of the major problems in 
defining the development of SC from neural crest cells is the absence of 
early differentiation markers. 
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Fig. 1.6: Schematic illustration of the main cell types and developmental transitions 
involved in Schwann cell development. Dashed arrows indicate the reversibility of the 
final, largely postnatal transition during which mature myelinating and non-myelinating 
cells are generated. The embryonic phase of Schwann cell development involves three 
transient cell populations. First, migrating neural crest cells. Second, Schwann cell 
precursors (SCPs). These cells express various differentiation markers that are not found 
in migrating neural crest cells, including brain fatty acid-binding protein (BF ABP), 
protein zero (PO) and desert hedgehog (DHH). At anyone time, a rapidly developing 
population of cells - such as the glia of embryonic nerves - will contain some cells that 
are rather more advanced than others. Third, immature Schwann cells. All immature 
Schwann cells are considered to have the same developmental potential, and their fate is 
determined by the axons with which they associate. Myelination occurs only in Schwann 
cells that by chance envelop large diameter axons - Schwann cells that ensheath small 
diameter axons progress to become mature non-myelinating cells. (Adapted from Jessen 
and Mirsky, 2005) 
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In rat sciatic nerve at E 14 precursor SC present sheath like processes, 
which contact each other and divide groups ofaxons into large bundles. 
PO mRNA can be considered as another precocious marker of a population 
of neural crest cells: during development, in fact, it is expressed at very 
low levels, in precursor and immatw'e SC, regardless of whether they are 
destined to become myelinated or non-myelinated (Bhattacharyya et al., 
1991; Lee et al., 1997). In order to survive, SC precursors need an 
axonally derived signal. In vitro data support this hypothesis: in fact if SC 
precursors are dissociated from the neurons and they are put in culture, 
they die; moreover, their programmed cell death can be rescued by adding 
conditioned medium from post-natal day 1 Dorsal Root Ganglia (DRG) 
neurons to the cultures, or putting SC precursors in close proximity to 
neurites of DRG neurons or finally exposing the cultures to axonal 
membranes isolated from cultured DRG neurons (Jessen et al., 1994; 
Dong et aI., 1995). These in vitro findings were confirmed in vivo in chick 
embryos, where programmed cell death of Schwann cells occurs both 
during normal development and after axonal degeneration induced by 
neurotoxin treatment. Interestingly, in those embryos Schwann cell 
apoptosis during development coincides with normally occurring 
motoneuron death. All together these in vitro and in vivo data indicate that 
axonal-derived trophic signals are involved in the regulation of Schwann 
cell survival in peripheral nerves during development. This axonal signal 
is f3 Neuregulin I(NRG) (Mirsky and Jessen, 1999). Four different genes 
code for neuregulins: NRG-l, NRG-2, NRG-3 and NRG-4. Little is known 
of the role of NRG-2, NRG-3 and NRG-4, whereas NRG-J has been shown 
to be fundamental for SC and OL survival and differentiation. 
Neuregulins are a family of growth factors, characterised by the 
combination of different domains: an Epidermal Growth Factor (EGF)-
like motif, a signal peptide, an immunoglobulin (Ig)-like domain, a 
cysteine-containing N-terminal domain, a glycosylation domain and a 
transmembrane domain. All NRG-1 isoforms can be proteolytic ally 
cleaved and released from the cell surface. 
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In El4 rats, the beta fOlms of NRG prevent apoptosis of Schwann 
cell precursor and stimulate DNA synthesis. When precursors are exposed 
to NRG in defined medium, they generate Schwann cells, with a time 
course that is similar to that occurring in embryonic nerves in vivo; 
moreover, if SC precursors are exposed to the extracellular domain of the 
ErbB4 NRG receptor, a protein that specifically blocks the action ofNRG, 
the neuronal signal that mediates precursor survival and maturation can be 
blocked (Dong et aI., 1995). These in vitro findings are suppOlied by in 
vivo data generated in 13 neuregulin 1 null mice: neuregulin -/- embryos 
die during embryogenesis, due to cardiac malformations. Interestingly, 
before the embryos die, they are almost completely devoid of SC 
precursors (Meyer and Birchmeier, 1995). 
NRG-l is expressed at the right time and place to act as signal 
. from neurons to precursors, but also to play a role at later stages of 
development. In fact, the level of NRG-l protein in adult mice is strongly 
reduced as compared to rat embryos at E 14 through to adult life. 
(Bermingham-McDonogh et aI., 1997; Marchionni et al., 1993). 
The four members of the EGF family of receptor tyrosine kinases, 
ErbBI (EGF-receptor), ErbB2, ErbB3 and ErbB4, function as receptors 
for neuregulins. The different ErbB receptors contain a large extracellular 
ligand-binding domain, a single transmembrane domain and an 
intracellular part with a COOH-tail and a tyrosine kinase domains, with 
few exceptions: ErbB2 has no affinity for NRGs, while ErbB3 receptor 
lacks the tyrosine kinase activity. The ErbB receptors usually form 
heterodimers on the cell surface, with nearly all the possible combinations, 
in a process of ligand induced dimerization, in which one of the other 
ErbB members is recruited as co-receptor. Finally, ligand-binding 
mechanism leads to receptor phosphorylation and activation of 
downstream signalling pathways. 
Many of these receptors are expressed in neurons and in glial cells 
during development (Burden and Yarden, 1997). The ErbB2IErbB3 
heterodimer is the primary NRG-l receptor in SC (Canoll et aI., 1996). In 
vivo data coming from engineered mice support this finding: first, 
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knockout mice for ErbB3 die soon after bilih, and their nerves are devoid 
of SC (Riethmacher et aI., 1997). Second, like ~-NRG null mice, mice 
lacking ErbB2 receptor die from cardiac defects, at an embryonic stage in 
which it is not possible to evaluate the effect on SC development. Third, 
some knock-out animals with cardiac rescue of erbB2 survive until birth 
and completely lack SCs (Lee et aI., 1995; Garratt et aI., 2000; Lin et aI., 
2000). 
The survival and progression of Schwann cell precursors to 
Schwann cells is regulated in vitro and in vivo by another family of 
factors, endothelins (ETs). In vitro data confirm this role for ETs: in fact, 
when added in vitro to rat Schwann cell precursors, ETs promote survival 
without stimulation of DNA synthesis (Brennan et aI., 2000). This action 
of ETs is mediated by the ET(B) receptors, that are expressed in 
developing peripheral nerves. Interestingly, within the complex growth 
factor interactions controlling the timing of Schwann cell development in 
embryonic nerves ETs seem to act as negative regulators of Schwann cell 
generation: in fact, in the combined presence of ~-neuregulin and ETs 
Schwann cell generation is significantly slower than in f3-neuregulin alone. 
A further in vivo confirn1ation of these in vitro data came from the 
characterization of spotting lethal rats, in which functional ET(B) 
receptors are absent: these animals presented accelerated expression of the 
Schwann cell marker S 100 in developing nerves (Brennan et aI., 2000). 
• 1.6.3 Precursor- immature SC transition 
This transition occurs between E14 and E17 in rat and in vivo it is 
characterized by a series of morphological changes mainly related to 
regulation of survival and response to mitogens. As opposed to Schwann 
cell precursors, immature SC can survive when cultured at high density in 
a defined medium without external addition of NRG or DRO conditioned 
medium (Jessen et aI., 1994). As SC mature in peripheral nerves, they 
move gradually from axon-dependent to axon-independent survival. This 
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capacity of SC to survive for an extended period of time in the absence of 
axons is crucial for nerve regeneration: for example, during Wallerian 
degeneration, near the lesioned point a retraction of proximal and distal 
stumps of the nerve occurs; as a consequence, SC de-differentiate to an 
immature phenotype and provide both trophic factors and adhesive 
substrates that promote axonal growth in the distal stamp. The ability of 
Schwann cells to survive without axons is due to the establislunent of an 
autocrine survival loop that is absent in precursors. Insulin-like growth 
factor, neurotrophin-3, and platelet-derived growth factor-BB are 
important components of this autocrine survival signal. Schwann cells 
have receptors for these factors: when they are applied at very low 
concentrations in Schwann cell conditioned medium, they promote and 
support survival; moreover, if the action of these factors is blocked (using 
specific blocking antibodies) the SC survival activity is blocked (Meier at 
aI., 1999). Finally, another factor secreted by SC that can promote SC 
survival in the presence of other growth factors is Leukemia Inhibitory 
Factor (LIF) (Dowsing et aI., 1999). 
In addition to positive survival signals, other factors that actively 
promote apoptosis may also play an important role in SC death after 
injury: the Nerve Growth Factor (NGF) promotes cell death in SC, via the 
p75 neurotrophin receptor (Soilu-Hanninen et ai., 1999). Finally, TGFI3 
can have a similar effect on developing SC, both in vitro and in vivo 
(D' Antonio et al., 2006). 
• 1.6.4 Immature to mvelinating or non-mvelinating SC transition 
Once formed, immature SC invade bundles ofaxons and sort them 
into smaller groups. Depending on the size ofaxons, they associate with 
only one large axon or with multiple small caliber axons, in order to adopt 
a pro-myelinating or a non pro-myelinating phenotype, respectively. The 
decision to become a myelinating versus non-myelinating SC is 
determined by cell-extrinsic signals coming from the axons. The identity 
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of the axonal signals responsible for this choice is not known, although it 
is determined by the axonal diameter; in fact only axons with a diameter 
bigger than Il-lm will become myelinated, whereas smaller axons will not. 
However, it has been recently demonstrated that NRG I Type III is 
involved in this choice, in fact myelinated axons express it at higher levels 
as compared to ensheathed axons; moreover, the analysis of neurons from 
NRG I Type III null animals revealed thinner myelin sheaths; lentiviral-
mediated expression of NRG 1 Type III in neurons is able to rescue these 
defects and drive Schwann cells to myelinate axons that would normally 
not be myelinated (Taveggia et aI., 2005). 
On the other hand, se also determine multiple properties ofaxons 
and neurons. They directly control the number of neurofilaments of the 
axons and their phosphorylation state. This is particularly important 
because a change in neurofilament number is imp0l1ant in determining 
axon diameter (Martini, 2001). As it is for Wallerian degeneration, this is 
another process where se exert a fundamental effect on neuronal final 
development. Further evidence of the reciprocal relationship of SC and 
axons comes from the analysis of the ErbB3 knock out mice: these mice 
die soon after birth, but their nerves are devoid of se, presumably because 
they lose se precursors even ifaxons can reach their normal target with 
normal innervation (Riethmacher et aI., 1997). However analysis of DRG 
survival in these mice revealed that 80% of them die before reaching the 
final target between E 13 and E 18, indicating that sensory neuron death is 
due to lack of se and their precursors. 
In addition to that, SC mediate also the spacing of Na + channel 
clusters along axonal membranes, during development of the Node of 
Ranvier (Salzer, 2002). Na+ channels are positioned in the middle of the 
Node of Ranvier and their distribution is particularly important for the 
saltatory conduction of impulses. Myelinating glia regulate the targeting of 
these channels at the Node of Ranvier, not only in the PNS, but also in the 
CNS (Boiko et aI, 2001). Other soluble factors could be involved in the 
clustering of these channels at the Node of Ranvier (Kaplan et aI., 1997; 
MaI1ini, 2001). 
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Finally, the effect of SC on the axons is proven by the fact that 
some of the mutations that cause human inherited neuropathies, such as 
Charcot Marie Tooth (CMT) disease, Dejerine Sottas Syndrome (DSS) 
and Congenital Hypomyelination (CH) disease, are due to a primary 
defect in SC. However, as a consequence of these mutations, some 
patients show also changes in the axons, such as reduced axonal caliber 
and alteration in the phosphorylation state of neurofilaments (Bjartmar et 
aI., 1999). These secondary defects affecting the axons could lead to 
axonal degeneration with subsequent severe clinical consequences 
(Sahenk 1999). 
All these observations strongly supp0l1 the existence of a strict 
reciprocal relationship between SC and axons. Both axons and SC 
cooperate for development and maintenance of the PNS. 
Finally, immature SC can generate also non-myelinating SC: these 
cells can be identified by the expression of several characteristic surface 
markers such as p75, Glial Fibrillary Acidic Protein (GFAP), N-CAM, Ll, 
GAP-43. These markers are all suppressed in myelinating Schwann cells, 
when the myelination process takes place (Fig. 1.7). 
1.7 Transcriptional control during SC development 
Although the molecular identity of the axonal signals that induce 
the myelinating or non-myelinating phenotype in SC is only partially 
known, relevant infonnation on the transcription factors regulating 
myelination in SC is broader. Three transcription factors are known to be 
important in the development of the glial lineage: the first of these, Sox 10 
has been discussed in a previous section, the other two, Oct 6 (also known 
as SCIP and Tst 1) and Krox 20 are both involved in the myelination 
program and are important for the topic of this thesis. 
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Fig. 1.7: Changes in phenotypic profile as cells progress through the embryonic Schwann 
cell lineage. Shared profiles are indicated by distinct colours. The boxes above the 
lineage drawing indicate the changes in gene expression that take place during embryonic 
Schwann cell development. The gene expression shown here is based on observations of 
endogenous genes rather than on observations of reporter genes in transgenic animals. 
Each developmental stage also involves characteristic relationships with surrounding 
tissues, and distinctive cell signalling properties (boxes below lineage drawing). For 
instance, neural crest cells migrate through extracellular matrix. By contrast, SCPs and 
Schwann cells are embedded among neurons (axons) with minimal extracellular spaces 
separating them from nerve cell membranes, a characteristic feature of glial ceUs in the 
CNS and PNS. Basal lamina is absent from migrating crest cells and SCPs, but appears 
on Schwann cells. ' Proteins that also appear on neuroblasts/early neurones. tMarkers that 
are acutely dependent on axons for expression. §Glial fibrillary acidic protein (GF AP) is a 
late marker of in vivo Schwann cell generation, as significant expression is not seen until 
about the time of birth. GF AP + SCs can be distinguished from astrocytes for their 
peculiar shape. The expression of GF AP is suppressed in cells that form myelin but 
retained in non-myelin-forming Schwann cells. The early expression ofGFAP has not yet 
been carefully examined in mice. IISCPs have been shown to be S 100 calcium-binding 
protein (SlOO)-negative and Schwann cells SIOO-positive using routine 
immunohistochemical methods. (Adapted from Jessen and Mirsky 2005) 
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• 1.7.10c(-6ISCIPITstllPOU3F 
Oct-6/SCIP/TstllPOU3F belongs to the class III family of POU 
domain transcription factors. This family consists of two evolutionarily 
conserved regions, an amino terminal specific domain and a carboxy 
terminal homeodomain. In the SC lineage both Oct-6 mRNA and protein 
can be detected in SC precursors (Fig. 1.7), reaching a peak soon after 
birth. In adult Oct-6 is expressed at low levels in non-myelinating SC 
(Arroyo et aI., 1998; Blanchard et aI., 1996). In Oct-6 null mice SC reach 
the pro-myelinating phenotype, by achieving a 1: I relationship with 
axons, but animals die at birth from respiratory defects (Bermingham et 
aI., 1996). However a small number of knock out mice can survive, and 
these animals show only a delayed myelination (Jaegle et aI., 1996). An 
explanation for this rescue is that Oct-6 might be involved in determining 
the transition from pro-myelinating to myelinating SC. It is also possible 
that other POU genes compensate for its absence; this is the case for two 
different POU domain transcription factors, B111-2, that is normally 
expressed by the SC lineage and Bm-l that is not nOlmally expressed in 
Schwann cells; both proteins are able to rescue the developmental delay 
phenotype, when ectopically expressed in cultured Oct-6 null Schwann 
cells or in Oct-6 -/- animals (Jaegle et aI., 2003; Friedlich et aI., 2005). 
Other in vitro and in vivo studies, using a dominant negative fonn of Oct-
6, postulated that it can act as a negative transcriptional regulator and a 
general repressor for myelin genes in immature SC in vitro (Monuki et aI., 
1993; Weinstein et aI., 1995). However a recent paper showed that Oct-6 
is a direct Krox-20 activator. In particular the authors showed that it acts 
as a positive regulator at the beginning of the myelination process 
(Ghislain et ai., 2002). Thus, Oct-6 probably serves to regulate the timing 
of myelination by regulating the transition of SC from pre-myelinating to 
pro-myelinating and to the myelin-forming phenotype. 
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• 1.7.2 Krox-20 
Egr-2 (Krox-20) is a zinc finger transcription factor belonging to 
the Early Growth Response (Egr) family; it is expressed in the SC lineage 
(Fig. 1.7). This family includes also Egr-1. Egr-3 and Egr-4 genes. Krox-
20 contains different domains: a DNA binding domain, an activation 
domain and a domain that is able to interact with two co-factors NAB 1 
and NAB2 iliGF-IA-hinding protein) (Russo et aI., 1995; Svaren et aI., 
1996). The gene is activated around E 1 0.5; it is not expressed in SC 
precursors while it is present in the dorsal and ventral roots close to the 
neural tube. In the peripheral nerve Krox-20 is activated around E15, very 
likely with the acquisition of a one-to-one relationship between SC and 
axons. During adulthood, Krox-20 expression marks myelinating SC 
(Topilko et aI., 1997). This axonal regulation is evident after nerve 
damage. During Wallerian degeneration, SC de-differentiate to an 
immature SC phenotype, losing their myelin sheath, while Krox-20 is 
downregulated (Topilko et aI., 1997). 
The function of Krox-20 in myelination has been studied in 
engineered mice. Mice carrying a targeted deletion of Krox-20 die soon 
after birth, and in addition to defects in hindbrain segmentation and in 
bone formation, they are defective in SC differentiation (Topilko et aI., 
1994; Schneider-Maunoury et aI., 1993). All SC destined to meylinate in 
these mice acquire a one-to-one relationship with the axon, but they seem 
to be arrested at the pro-myelinating stage. This impairment is also 
paralleled by a strong reduction in the expression of PO, MBP and PMP22 
myelin genes. The peripheral nerves of the few animals that survive after 
birth were analyzed: in these nerves, both SC proliferation and apoptosis 
are increased as compared to controllittermates. Therefore, it is likely that 
Krox-20 is involved in regulating the transition into the pro-myelinating 
phenotype, not only by activating specific myelin gene expression, but 
also by inactivating different signaling pathways present in immature SC 
and responsible for the inhibition of their differentiation. One example is 
the c-Jun-amino-terminal kinase (JNK) pathway that is active in SC from 
E 18 to birth; this pathway is inactivated as SC start to myelinate with a 
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mechanism that is Krox-20 dependent (Topilko et al., 1994; Jessen and 
Mirsky, 2005). 
In humans, mutations in Krox-20 are associated with peripheral 
neuropathies such as CMT, CH and DSS neuropathies (Warner et al., 
1998; Warner et al., 1999). Co-transfection experiments show that Krox-
20 can partially trans-activate the PO promoter (Zorick et al., 1999). 
Another paper describes an induction of mRNAs for PO, MBP, MAG, 
PMP22 Cx32 and MAG by Krox-20 (Nagaraj an et al., 2001). Some of the 
mutations described in humans have a dominant negative effect on the 
wild type Krox-20, affecting, at the end, the expression of myelin genes. 
Recently, a highly conserved element has been found in the first intron of 
the Mpz gene, which contains binding sites for Krox20 and Sox 10 
transcription factors (LeBlanc et al., 2006; LeBlanc et al., 2007). Egr2 
mutants specifically affect this element in the Mpz first intron. Both Egr2 
and Sox 1 0 are able to bind this element, when myelination takes place in 
the sciatic nerve. A dominant Egr2 mutant does not impede Egr2 binding 
to Mpz, but reduces SoxlO binding to the Mpz intron element, thereby 
resulting in the disruption of the genetic program that controls myelination 
(LeBlanc et al., 2007). 
Another mutation that causes human neuropathy is recessive and is 
located in the Krox-20 domain interacting with the NAB transcriptional 
co-factors (Warner et al., 1999). The location of this mutation strongly 
suggests that NAB proteins, complexed with Krox-20, are key regulators 
of the Schwann cell myelination program. This hypothesis is supported by 
in vivo data coming from mice lacking both Nab! and Nab2; these mice 
show elevated Egr2 expression, but a severe congenital hypomyelination 
of peripheral nerves, with a block of Schwann cell development at the pro-
myelinating stage (Le et aI., 2005). 
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1.8 The Inherited Neuropathies 
The Inherited Neuropathies are a clinically and genetically 
heterogeneous group of diseases that affect the peripheral nervous system 
(PNS) and can result in a severe neuromuscular deficit. 
These neuropathies were first identified more than one century ago. In 
fact, in 1886 J.M Charcot and P.Marie in Paris, and T.T.Tooth in London 
described a syndrome, which they defined respectively as "une forme 
peculiere d'atrophie musculaire progressive" and "the peroneal type of 
progressive muscular atrophy". The syndrome, that carries their names, 
was characterized by a decrease in strength and distal muscular atrophy, a 
minimal sensory component, the presence of foot deformities, a rare, but 
present, infantile onset and a frequent familiar recurrence (Charcot, Marie, 
1886; Tooth, 1886). Due to the vast clinical heterogeneity of these 
diseases, a chaotic classification followed the first description, where 
ambiguous and overlapping definitions were used ("Charcot-Marie-Tooth 
disease", "peroneal muscular atrophy", "hypertrophic neuropathy", 
"Dejerine-Sottas disease or syndrome", "Roussy-Levy syndrome" -
Harding and Thomas, 1980). The coming of electromyographical (EMG) 
techniques produced a significant improvement in the nosography of 
inherited neuropathies. At present, the most used clinical classification 
(Dick et a1. 1983) includes eight different types of Hereditary Motor and 
Sensory Neuropathies (HMSN), subdivided by means of clinical and 
electromyographical repOlis. Only three types of HMSN exclusively affect 
the PNS, while in the other forms the neuropathic status is associated with 
other neurological and non-neurological problems. 
HMSN I (demyelinating or type 1 Charcot-Marie-Tooth disease) 
and HMSN III (Dejerine-Sottas disease) are characterized by a moderate 
to severe reduction in motor nerve conduction velocities (NCV - in 
normal individuals it reaches 40-50 mfs, while in affected patients it goes 
down to 10-30 mfs); the very early onset and the higher severity 
distinguish HMSN III from HMSN I. 
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On the other hand, HMSN II (axonal or type 2 Charcot-Marie-
Tooth disease) is characterized by slight or absent reductions in NCV, 
accompanied with EMG signs of chronic axonal damage. 
Recently, in the last decade, the identification of HMSN patients 
with mutations in specific myelin genes moved the principles of 
classification from the clinical-electrophysiological phenotype to the 
original genetic alteration. So far, myelin gene defects were identified in 
patients suffering from Charcot-Marie-Tooth type 1,2 and 4 diseases, 
Dejerine-Sottas disease, Hereditary Motor and Sensory Neuropathy with 
Liability to Pressure Palsies and Congenital Hypomyelination (Fig. 1.8). 
• 1.8. J Charcot-Marie-Tooth disease (CJvfT) 
CMT. is the most common inherited peripheral neuropathy in 
humans, with a prevalence of 40 in 100000. According to 
electrophysiological reports, two distinct forms of CMT can be identified, 
one demyelinating (CMT 1) and one axonal (CMT 2) (Lupski et aI., 1991; 
Kaku et aI., 1993; Dyck et aI., 1983). 
1.8.1.1 CMT 1, the most frequent form of CMT, is caused by 
abnormalities intrinsic to the Schwann cells, the myelin-producing cells of 
the pelipheral nervous system; therefore it is associated with severe PNS 
demyelination, as demonstrated by slowed nerve conduction velocities; its 
onset usually occurs in the first two decades and is characterized by a 
progressive distal muscular strength deficit (Lupski et aI., 1991): Patients 
may require foot care (pes cavus and pes equinovarus) or bracing to 
ambulate normally (steppage gait), and sometimes become unable to 
walk. Usually osteotendinous reflexes are absent or very weak and rarely, 
a sensory impairment is present. The typical electrophysiological reports 
are always present in CMT 1 patients several years before clinical disease 
onset (Kaku et aI., 1993; Garcia et aI., 1998). From the histopathological 
point of view, peripheral nerves of affected individuals present a reduction 
in the number of myelinated fibers, characterized by very thin sheaths and 
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the emergence of hypertrophic "onion bulb changes", that represent 
morphological features of a chronic process of 
demyelinationlremyelination (Dyck et aI., 1983). A trait of CMT 1 
patients is the huge clinical variability, observed not only in unrelated 
individuals (Lupski et aI., 1991), but also between members with a 
common pedigree (Kaku et aI., 1993) and even between identical twins 
(Garcia et aI., 1995) . 
. Type I CMT is usually inherited as an autosomal dominant 
disorder, although recessively inherited, sporadic and X-linked forms do 
occur. According to genetic linkage analysis data, CMT 1 has been 
subdivided in: 
- CMT lA, with linkage on chromosome 17pl1.2 (Vance et a1. 
1989). About 90% of CMT 1 patients are CMT lA; the disease condition 
is most commonly due to segmental duplication of a region of 
chromosome 17 (71 % of all CMT lA cases), leading to the presence of an 
extra copy of the gene for peripheral myelin protein 22 (PMP22) (Lupski 
et aI., 1991; Raeymaekers et aI., 1991, 1992; Nelis et aI., 1999). 
Inheritance is autosomal dominant in pattern and analysis of nerve 
biopsies suggests that the disorder is caused by increased gene dosage 
(Hanemann et aI., 1994; Yoshikawa et aI., 1994; Vall at et aI., 1996). As 
demonstrated by Pentao et aI., in 1992, the duplication arises from an 
unequal crossing-over and recombination occurring between homologous. 
sequences flanking the duplicated genomic region. The clinical symptoms 
in patients carrying the duplication may appear in the first decade or early 
in the second decade. Muscle weakness starts in the feet and legs. Infants 
and children manifest the disease by walking on their toes and inability to 
walk on their heels. Older patients consult a physician because of 
abnormality of the gait, foot deformities, or loss of balance. Steppage or 
equine gait, pes cavus deformity and claw toe are usually present in 
CMTIA patients. Hand tremors are a frequent complaint and are most 
likely related to hand weakness or to coexisting essential tremor. 
Enlargement of nerves can be seen or palpated, predominantly in male 
patients. Muscle stretch reflexes disappear early in the ankles and later in 
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Fig. 1.8: In the last decade, several studies contributed to the identification of HMSN 
patients with mutations in specific myelin genes. In this schematic view of myelinated 
axon and myelinating Schwann cell, the localization within the cell of some proteins 
mutated in patients with inherited neuropathies is illustrated. The region enclosed in the 
rectangle on the bottom panel is shown in detail on the top. MPZ is localized to compact 
myelin, whereas ex 32 is localized to the paranodal loops, incisures and inner mesaxon 
composed of noncom pact myelin. (The figure has been adapted from Shy et aI., 2002) 
51 
the patella and upper limbs. The plantar responses are frequently absent. 
Finally, mild sensory loss may be seen in some patients. 
Occasionally, CMT lA has been demonstrated to result from 
PMP22 point mutations. The clinical features of these patients show 
severe disease in childhood and higher reduction in nerve conduction 
velocities, as compared to individuals having the duplication. In fact, point 
mutations in the PMP 22 have been found in patients that have been 
diagnosed with a more severe form of HMSN, the Dejerine Sottas 
syndrome (Hayasaka, 1996). 
- CMT 1B, with linkage on chromosome lq22-q23 (Bird et aI., 
1982). CMT 1 B represents approximately 5-10 % of families with CMT 1 
phenotype, and it has been shown to be associated with mutations in the 
gene coding for PO (Hayasaka et aI., 1993; Kulkens et aI., 1993). From a 
clinical perspective, an earlier onset of the symptoms manifested by 
delayed ability to walk, proximal leg weakness without decreasing 
ambulation, and slower motor NCVs are the only differential points with 
CMT lA. Nevertheless, a great variability of disability can be observed 
also in CMT 1 B patients, even in members of the same family (Szabo et 
aI., 2005). That is the reason why, for a definite diagnosis of CMTs in 
general, the DNA test is required. The morphology of sural nerve biopsy 
of confirmed CMT 1 B cases shows a demyelinating process with onion 
bulb formation. Ultrastructural alterations consist of uncompacted myelin 
in agreement with the accepted function of PO as a homophilic adhesion 
molecule (Gabreels-Festen et aI., 1996): To date over 110 different 
mutations in MPZ have been identified, that result not only in the mild 
CMT IB phenotype, but also in more severe phenotypes like Dejerine-
Sottas syndrome and Congenital Hypomyelination. 
- CMT X, the X-linked form of demyelinating CMT, accounts for 
7 -10% of CMT. It is caused by point mutations in the connexil1-32 gene, a 
gap junction protein expressed in myelinating Schwann cells in the 
paranodal loops and Schmidt-Lanterman incisures (=SLI), but not 
incorporated into the myelin sheath (Bergoffen et aI., 1993). CMT X is 
mainly inherited as a dominant form (about 90% of the cases). The clinical 
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features and clinical variability are similar to the CMT 1 A and 1 B 
patients, but the family pedigree reveals lack of male-to-male transmission 
and, moreover, the affected males have more severe phenotypes than the 
affected females. The nerve conduction studies have shown intermediate 
motor slowing in most families; the velocities are usually between 30 and 
40 mls in males and can be faster or near-normal in females: these values 
are consistent with a demyelinating form of the disease (Bergoffen et aI., 
1993; Nicholson and Nash, 1993; Lewis and Shy, 1999). However, there 
are intriguing reports describing CMT X patients with primarily axonal 
features on electrophysiological and morphological analyses (Timmerman 
et a11996; Birouk et a11998; Gutierrez et aI., 2000; Hattori et aI., 2003). 
- Finally, an additional, less common form of CMT1, sometimes 
indicated as CMT IC, exists; it refers to a group of CMT 1 with no 
detectable mutations in PMP 22 or MPZ genes. Two causative genes have 
been identified so far: the egr 2 gene on chromosome 10q21-22A, coding 
for the zinc finger transcription factor EGR2, expressed in myelinating 
Schwann cells and discussed above (Warner et aI., 1998), and a putative 
protein degradation gene, LITAFISIMPLE, on chromosome lOp13.l-12.3, 
coding for a ubiquitous lysosome protein that may be involved in cell 
proliferation and apoptosis (Street et aI., 2003; Bennett et aI., 2004). 
1.8.1.2 CMT 2 (or Type II) is the axonal or neuronal form of 
CMT; it has been previously suggested to represent about one-third of 
autosomal dominant CMT families. CMT 2 is mainly distinguishable from 
CMT 1 by the presence of normal or slightly slowed NCV; the classical 
clinical symptoms are similar to the ones of CMT 1 patients, but some 
differences are present: the onset usually occurs later, hypertrophic 
changes on biopsies are absent and foot muscle weakness is often more 
severe. Morphological studies on patient biopsies showed only occasional, 
small onion bulbs, but mainly a reduction in the number of myelinated 
fibers, more pronounced distally. Nevertheless, the clinical phenotype 
within the CMT 2 subgrouping can vary more than CMT 1. Due to the 
absence of the electrophysiologic changes, peculiar to CMT 1, CMT 2 is 
more difficult to diagnose. 
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Several unique genes have been found for eMT 2, mapping to at 
least seven distinct loci and originating the different forms of axonal 
eMT. Between them: a mitochondrial membrane protein AIFN2 
(Mitofusin2), a protein involved in axonal transport KIF 1 B (Kinesin 
family member IB), a protein involved in endosomal trafficking RAB7 
(Ras-associated protein), a protein involved in RNA processing GARS 
(Glycil-tRNA synthetase), a neuronal structural protein NEFL 
(Neurofilament light), a protein involved in chromatin organization 
LMNA (Lamin NC), a heat-shock 27-kD protein-l (HSPBl) and finally 
PO (Zuchner and Vance, 2006). The classification of eMT 2 subgroups is 
actually based on the genomic linkage analyses; some of these forms 
present the classical eMT 2 phenotype, while others are characterized by 
specific clinical findings: 
- CMT 2A was mapped on chromosome 1 p35-36 (Ben Othmane 
et aI., 1993), in an area that is believed to be gene rich; this, coupled with 
the instability of the region, has made progress on identifying this locus 
very difficult. Patients show the traditional eMT phenotype. Recently it 
has been linked to mutations in MFN2 (Zuchner et aI., 2004) and KIFIB 
(Bissar-Tadmouri, 2004) 
- CMT 2B mapping on chromosome 3q13-22 (Auer-Grumbach et 
aI., 2000). Families with CMT 2B are likely to be distinct in their clinical 
presentation, with sensory symptoms being unusually severe; patients; in 
fact, commonly had ulcerations leading to amputations of the feet. 
Recently it has been linked to mutations in RAB7 (Houlden et aI., 2004) 
- CMT 2C, in 2003 Klein and colleagues found linkage to a 
region at 12q23-q24. Patients suffering from this subfoffil of type II CMT 
have been noted to have diaphragm and vocal cord paresis that can lead, in 
most severe cases, to respiratory failure (Dyck et aI., 1994). No gene has 
been yet associated to this subform. 
- CMT 2D, mapped on chromosome 7p14 and sometimes 
associated with an upper extremities onset of symptoms (Ionanescu et aI., 
1996). Screening of different families diagnosed with CMT2D led to the 
identification of a mutation in the GARS gene (Antonellis et aI., 2003). 
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- CMT 2E, related to a mutation In the NF-L gene on 
chromosome 8p21 (Mersiyanova et aI., 2000). 
- CMT 2F, linkage of the disorder has been found on 
chromosome 7qll-q21 (Ismailov et aI. 2001). Affected members of two 
different families showed mutations in the HSPB 1 gene (Evgrafov et aI. 
2004). 
- CMT 2 with MPZ mutations, characterized by the classical 
axonal CMT phenotype (Marrosu et aI., 1998; Senderek et aI., 2000; 
Boerkoel et aI., 2002). 
- Autosomal recessive CMT 2, mapped on chromosome 1 q21.2 
q21.3 (Bouhouche et aI., 1999). In 3 consanguineous Algerian families 
with autosomal recessive CMT2 linked to chromosome lq21, a 
homozygous mutation in the LMNA gene was identified (De Sandre-
Giovannoli et aI. 2002). 
1.8.1.3 CMT 4 is an autosomal recessive form of CMT, with 10 
loci and five causative genes identified. According to the disrupted gene, 5 
different forms of CMT 4 has been identified: 
- CMT 4A, mapped on chromosome 8q21 and often classified as 
a recessive form of an axonal CMT. CMT 4A patients carry mutations in 
the GDAP 1 gene. This gene is predominantly expressed in neural tissue, 
including brain, spinal cord, dorsal root ganglia and sural nerve and it is 
probably involved in neural differentiation (Cuesta et aI., 2002). CMT 4A 
is characterized by early age of onset, severe sensorimotor impairment and 
foot deformities. Nerve conduction studies and nerve biopsy findings are 
highly variable both between families and within families, some showing 
prominent demyelination while others showing primary axonal 
degeneration (Nelis et aI., 2002). 
- CMT 4B, mapped on chromosome l1q22 (Ben Othmane et aI. 
1999). It is a recessively inherited demyelinating neuropathy characterized 
by early onset (age 2-3 years), severe phenotype (loss of ambulation in 
adult), mild facial weakness and hearing loss in some patients, and 
demyelination with distinct redundant focally folded myelin shown on 
nerve biopsies (Quattrone et aI., 1996; Gambardella et aI., 1999). The 
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defective genes have been identified: one is myotubularin-related protein 2 
(MTMR2) gene, encoding a ubiquitously expressed dual specificity 
phosphatase, whose main substrate are phosphorylated phosphoinositides 
(Bolino et al., 2000; Nelis et al., 2002; Berger et al., 2002); the second one 
is the myotubularin-related 13 (MTMRJ 3) gene, coding for a protein in 
which key catalytic residues are missing ("pseudophosphatase", Azzedine 
et al., 2003). 
- CMT 4C, linked to chromosome 5q23-33; the presenting 
problem of CMT 4C is disabling scoliosis, usually apparent by age 10 
years. The severity of distal sensorimotor neuropathy varies and foot 
deformities are common. Sural nerve biopsies show demyelinating 
features with focal myelin thickenings (Gabreels-Festen et a1., 2002). The 
disrupted gene has been identified with the SH3TC2 gene (or KlAA1985; 
Senderek et al., 2003). 
- CMT 4D, mapped on chromosome 8q24.3 and also known as 
hereditary motor and sensory neuropathy-Lorn type (HMSN-LOM); it is a 
demyelinating neuropathy that presents at age 5-6 years with gait 
difficulty from leg weakness and is associated with hearing loss. It was 
initially identified in the gypsy community. A homozygous nonsense 
mutation in the N-myc downstream-regulated gene 1 (NDRGJ) has been 
found in all affected individuals. NDRG 1 is a ubiquitous gene with the 
highest levels of expression in Schwann cells and with no expression in 
axons, probably involved in the Schwann cell-axon interaction 
(Kalaydjieva et al., 2000). 
- CMT 4F, mapped on chromosome19q13, is a sensory-motor 
demyelinating neuropathy with neuropathic pain. It is caused by 
homozygous mutations in periaxin (Guilbot et al., 2001). Periaxin 
mutations can cause recessively inherited demyelinating neuropathies with 
a broad variety of phenotypes, ranging from Dejerine-Sottas disease to 
CMT 4F. Hearing loss is a distinctive associated feature of CMT 4F 
patients. Nerve biopsies show evidence of demyelination and 
remyelination with some onion bulb formation and segments of 
hypermyelination (or tomacula) that can contribute to unusual 
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susceptibility to fiber dysfunction or degeneration after modest 
compression (Takashima et aI., 2002). 
• 1.8.2 De;erine-Sottas Disease (DSD) 
With this name is indicated a third fonn of Hereditary Motor and 
Sensory Neuropathies, equivalent to HMSN III and sometimes also 
indicated as CMT type 3; it is defined as a severe demyelinating 
neuropathy, presenting in infancy with delayed motor development, very 
slow nerve conduction velocities (less than 10-12 mls) and usually 
elevated Cerebro-Spinal Fluid (CSF) proteins. Progression is severe and 
walking is lost early. Inheritance is thought to be autosomal dominant 
(Dyck et aI., 1975). Hypomyelination of the peripheral nerves is seen as a 
pathological hallmark and it is more severe than in CMT patients. Classic 
onion bulbs, made of concentric thin Schwann cell lamellae, and myelin 
breakdown products were considered evidence of an ongoing 
demyelinating process (Dyck et aI., 1971; Ouvrier et aI., 1987). Recent 
genetic investigations showed that several of the earlier published cases of 
DSD result from de novo heterogeneous dominant point mutations of the 
PMP 22 gene (Roa et aI., 1993; Gabreels-Festen et aI., 1995; Valentijn et 
aI., 1995), or the MPZ gene (Hayasaka et aI., 1993; Nakagawa et aI., 
1999). More recently it has been demonstrated that also autosomal 
dominant mutations of EGR2 might result in DSD (Warner et aI., 1998). 
Furthennore, an autosomal recessive inherited fonn of DSD may result 
from mutations in the periaxin gene (PRX - Boerkoel et aI., 2001). In 
addition, one mutation in the inhibitory domain of EGR2 and at least one 
PMP22 mutation in the C-tenninal intracellular domain of the protein are 
inherited as an autosomal recessive trait (Warner et aI., 1998; Pannan et 
aI., 1999). These mutations are silent in the heterozygous parents, but 
cause a DSD in the homozygous children. Two specific mutations of MPZ 
lead to a DSD phenotype in the homozygous state, but result in a mild 
CMT phenotype in the heterozygous state (Ikegami et aI., 1996; Pareyson 
et aI., 1999). Finally, the phenotypic expression of the few reported cases 
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of a homozygous PMP22 duplication may cause a DSD (LeGuern et al., 
1997; Sturtz et al., 1997). 
• 1.8.3 Congenital Hvpomvelination Nellropathy (CHN) 
Lyon in 1969, and Kennedy and colleagues in 1977 had discerned 
a variant of HMSN III, distinct from DSD; they called it Congenital 
Hypomyelination Neuropathy (CHN) and defined as a severe neuropathy 
with a congenital or early infantile onset; peripheral nerve biopsies from 
CHN patients present no or extremely thin myelin sheaths and atypical 
onion bulbs of mainly basal lamina (Bornemann et al., 1996). Several 
cases with a similar pathology have been described, with distal muscle 
weakness, hypotonia, areflexia, and severe slowing of nerve conduction 
velocities. The findings of CHN patients led CHN to be considered 
distinct from DSD, the first being a non-progressive disorder with a defect 
in myelin formation and the second a progressive demyelinating disorder 
(Harati and Butler, 1985). In most severe cases of CHN, articular 
contractures or arthrog'yposis multiplex congenital are reported (Boylan 
et al., 1992). The majority of CHN cases occurred sporadically, but in 
some of them clear evidence of autosomal recessive inheritance was 
present. Although CHN is a distinct clinical entity, it may share similar 
genetic features with DSS; in fact molecular genetics analysis of CHN 
patients revealed mutations in genes coding for MPZ (Warner et al., 1996; 
Mandich et aI., 1999), PMP 22 (Fabrizi et aI., 2001) and EGR 2 (Warner 
et aI., 1998). 
• 1.8.4 Hereditary Neuropathy with Liability to Press lire Palsies 
(HNPP) 
Hereditary neuropathy with liability to pressure palsies (HNPP) is 
a frequent demyelinating neuropathy (10 to 50 per 100.000), which is 
sometimes classified with the CMT 1 syndromes because of its genetic 
and functional relationship to the latter group of peripheral neuropathies. 
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HNPP is an autosomal dominant disorder, first described by De Jong in 
1947 and often viewed as an entrapment or compressive neuropathy that 
may affect the peroneal, median or ulnar nerves at vulnerable sites. The 
onset of HNPP is usually in childhood or adolescence. When palsies 
occur, they may be debilitating in that they may last for days to weeks and 
may require installation of a lower limb brace in the cases of prolonged 
peroneal palsies. The abnormal neurophysiological features of HNPP are 
consistent with demyelination, showing mildly prolonged motor and 
sensory nerve conduction velocities in a symmetrical, generalized pattern. 
Mild electrophysiological signs of demyelination are present also in 
nerves not affected by palsy (Earl et aI., 1964). Histological assessment of 
sural nerve biopsies reveals the presence of tomaculi, the pathological 
signature of HNPP in which there is massive redundancy or overfolding of 
layers of the myelin sheath, with predominance in the paranodal region. 
Rare patients showing axonal regeneration and lacking tomacula have 
been observed (Sessa et aI., 1997). The spectrum of clinical presentation in 
HNPP is broad and may range from clinically asymptomatic persons 
(obligate gene carriers), to those who more typically present with recurrent 
palsies and in some advanced cases may mimic smouldering forms of 
CMT 1. 
The genetic locus for HNPP maps to chromosome 17p 11.2-12, where it is 
often associated (90% ofHNPP cases) with a large 1.5-Mb DNA deletion, 
involving the same DNA fragment that is duplicated in CMT lA patients 
and that harbors the peripheral myelin protein-22 gene (Chance et aI., 
1993). Rarely, point mutations have been observed in HNPP patients 
(Nicholson et aI., 1994; Lenssen et aI., 1998; Sahenk et aI., 1998). 
1.9 Animal models of CMT disease 
As we have seen in the prior chapter, even if genetically 
heterogeneous, the CMT phenotype is similar among the majOIity of 
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patients and includes progressive distal weakness and wasting in the limbs 
with less evident sensory loss, deformities in the feet and reduced or 
absent tendon reflexes. Even if the majority of CMT disorders start as 
demyelinating diseases, disability in the patients mainly correlates with 
axonal damage; essentially, most of CMTs evolve to a disturbance of the 
SC/axon unit, rather than isolated damage to myelin-forming SC or axons. 
In order to clarify the pathogenetic mechanisms of the different CMT 
neuropathies, animal models have taken on a key role. In fact, it is there 
that the normal three-dimensional and reciprocal relationships between SC 
and axons can be highlighted and that pathologic changes can be 
monitored, with the aim of understanding first how mutations in different 
genes, some of which are expressed specifically by SC, can lead to similar 
disabilitating axonopathies, and second how the different CMT 
phenotypes (CMTI, DSS, CH and CMT2) can be generated from different 
mutations in the same gene. 
Here below I include a short review of the main CMT animal 
models known so far, that can be somehow helpful for the purpose of this 
thesis. 
• 1.9.1 PMP22 animal models 
As discussed in the dedicated chapter, mutations affecting the PMP22 
gene are the most frequent causes of inherited peripheral neuropathies 
(Fig. 1.9). Various animal models for PMP22 point mutations are 
currently available. Some of them carry naturally occurring PMP22 
mutations (Tr and Tr-J mice), while others were artificially generated 
through common transgenic techniques (PMP22 transgenic mice; PMP22 
transgenic rats; conditional PMP22 overexpressing mice and mice with 
decreased PMP22 gene dosage). 
1.9.1.1 Trembler mouse: this spontaneous mouse mutant was 
described more than 50 years ago (Falconer, 1951). It is characterized by 
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autosomal dominant inheritance, unsteady gait, weakness of the 
hindlimbs, axial tremor and stress-induced convulsions. The Trembler 
mutation is a Glycine to Aspartic Acid substitution at position 150, in the 
last hydrophobic domain of PMP22 protein (Suter et aI., 1992). The same 
mutation has been found in a family diagnosed with a severe DSS 
phenotype (Ionasescu et aI., 1997). Within the cell, the mutation leads to a 
trafficking defect of the PMP22 protein, associated with the high tendency 
of the Tr protein to form aggregates (Tobler et aI., 2002). At the 
morphological level, adult Tr mutants show severe hypomyelination of 
peripheral nerves, with increased SC number and SC proliferation (Perkins 
et aI., 1981; Sancho et aI., 2001) and reduced NCV « 10 mls; Low and 
McLeod, 1975). During development, the onset of myelination is delayed: 
Schwann cells are late in progressing from the promyelination stage to 
myelination (Henry et aI., 1983). Finally, hypomyelination in the Trembler 
mutant mice is associated with a general downregulation of myelin protein 
components, including PMP22; in fact quantitative and qualitative 
immunocytochemical analysis performed in the sciatic nerve of the Tr/+ 
mouse showed a significant decrease in PMP22, PO and MBP (Vallat et 
aI., 1999). 
61 
Missense 
Nonsense Mutation 
Deletion Mutation 
Insertion 
~lelion&lnsertion 
PMP22 (PMP22) 
CHN ' e MTt 
DSS DSS CMT I ~pp CC .. H 0 
t) 9 
-& -0-~-@-
~ ~ 
~ ~ 
Frameshilt , ......... 1 V / 
Possible Polymorphfsm or Reoesslve Mutation 9 
Fig. 1.9: Schematic summary of how PMP22 mutations affect PMP22. The positions of 
the amino acids affected by the mutations, as well as their phenotypes, are indicated in 
the legend. N-linked glycosylation sites are shown (amino acid 41). Mutations that affect 
the splice sites are not depicted. The patients were classified according to the published 
information given in the references on the website (http ://molgen-
www.uia.ac.be/CMTMutations/DataSource/MutByGene.cfm). but in many cases this 
information is insufficient to make a definitive diagnosis. (Modified from KJeopa and 
Scherer, 2002). 
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1.9.1.2 Trembler-J mouse: it is again a spontaneous mutant mouse, 
carrying a missense mutation exchanging a Proline residue for a Leucine 
at position 16 in the first hydrophobic domain of PMP22 (Suter et aI., 
1992b). The same mutation has also been described in a family with a 
severe CMT 1 (Valentijn et aI., 1992). At the intracellular level, the Tr-J 
protein appears to reach the intermediate compartment between the 
endoplasmic reticulum and the Golgi, but cannot proceed further (D'Urso 
et aI., 1998; Tobler et aI., 1999). The pathology in adult heterozygous Tr-J 
mice is qualitatively similar (thinly myelinated axons, SC onion bulb 
formation, abnormalities in myelin compaction and perturbances of the 
axon-glia compartment), but less pronounced than in the Tr (Henry et aI., 
1983). 
1.9.1.3 PMP22 transgenic mouse: transgenic mice carrying 16 to 
30 additional copies of the PMP22 gene have been generated (Magyar et 
aI., 1996). These mice display a severe congenital hypomyelinating 
neuropathy, characterized by an almost complete lack of myelin and 
marked slowing of nerve conductions. An increased number of 
amyelinating Schwann cells can be found in affected nerves. These 
amyelinating SC do not form onion bulbs, but associate with axons. The 
expression of embryonic Schwann cell markers (p7SNTR, N-CAM and Ll) 
indicates that the mutant Schwann cells are characterized by a 
premyelination-like phenotype. In addition, Schwann cells continue to 
proliferate during adulthood. Thus, these data show that mutant Schwann 
cells are unable to proceed in their differentiation into the myelinating 
phenotype. Further analysis of PMP22 transgenics revealed that the 
mutant mice develop also a distally accentuated axonopathy. Interestingly, 
degenerating axons seem to be preferentially associated with 
demyelinating or dysmyelinating SC (Sancho et aI., 1999). In addition to 
these, another set of PMP22 trangenic lines, carrying fewer copies (about 
8 copies) of the gene, have been generated. These mice show a peripheral 
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neuropathy, similar to the human pathology: the disorder is dominant, 
causes progressive weakness of the hind legs, and there is severe 
demyelination in the peripheral nervous system including the presence of 
onion bulb formations (Huxley et aI, 1996). 
1.9.1.4 PMP22 transgenic rat: a single line carrymg three 
transgenic Pmp22 copies was generated (Sereda et aI., 1996). PMP22-
transgenic rats develop gait abnormalities caused by a peripheral 
hypomyelination, Schwann cell hypertrophy (onion bulb formation, 
suggesting active demyelination), and muscle weakness. Myelin 
abnormalities are more pronounced in ventral than in dorsal roots. 
Reduced nerve conduction velocities closely resemble recordings in 
human patients with CMTIA. Furthermore, when bred to homozygosity, 
transgenic animals completely fail to elaborate myelin. Trafficking of the 
overexpressed PMP22 myelin protein through the endoplasmic reticulum 
is not significantly impaired in fact the molecule acquires complex 
glycosylation and is blocked in the Golgi compartment. Finally, in 
PMP22-trangenic rats the program of myelin gene expression, analyzed 
using semiquantitative reverse transcription-PCR and 
immunofluorescence techniques, is not affected (Niemann et aI., 2000). 
1.9.1.5 Conditional PMP22 overexpressing mouse: this is a 
transgenic mouse model in which mouse pmp22 overexpression can be 
regulated. In this mouse model, Schwann cells specifically overexpress 
pmp22 in of the peripheral nerves; when the mice are fed with tetracycline 
overexpression is turned off. When pmp22 overexpression occurs, it 
causes demyelination. In contrast, when pmp22 overexpression is off, 
myelination is nearly normal. When overexpression of pmp22 is switched 
off in adult mice, correction begins within 1 week and lead to advanced 
myelination by 3 months. Nevertheless the myelin sheaths are still thinner 
than normal. Conversely, when the gene is upregulated in adult mice, 
active demyelination starts 1 week after and progresses for about 8 weeks. 
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All together these data indicate that Schwann cells with mature myelin are 
sensitive to increased amounts ofpmp22 (Perea et aI., 2001). 
1.9.1.6 Mice with decreased PMP22 gene dosage: mice with 
genetic disruption of the PMP22 gene have been generated (Adlkofer et 
aI., 1997); they present a delay in the onset of myelination and develop 
abundant tomacula at a young age. The presence in older animals of thinly 
myelinated axons and SC onion bulbs, together with very slow nerve 
conduction velocities indicate that the mice develop demyelination and 
remyelination. In homozygous Pmp22 null mice distal axonopathy 
develops: it differs from the one described in PMP22-transgenic mice 
because of the presence of clear signs of active axonal degeneration, like 
accumulation of dense bodies and vesicles, vacuolization of axonal 
organelles, disruption of the axolemma and disorganization of cytoskeletal 
elements. Heterozygous mutant mice are less affected than homozygous 
null animals, but they also exhibit focal tomacula (Sancho et aI., 1999). 
These sausage-like hypermyelination structures are comparable to the 
morphological features in hereditary neuropathy with liability to pressure 
palsies (HNPP). Therefore, analysis of knock-out animals indicates that 
Pmp22 is required for the correct development of peripheral nerves, the 
maintenance ofaxons and the determination of myelin thickness and 
stability. 
• 1.9.2 PO animal models: 
As previously discussed, more than 110 mutations MPZ have been 
identified, causing CMT IB in humans. They reach 4 to 14% of CMT not 
due to chromosome 17 duplication. No deletion or duplication of the gene 
has been reported, but only missense, nonsense and frameshift mutations,. 
Most of the mutations are distributed in the extracellular domain, but also 
mutations within the transmembrane and intracellular domains have been 
described. Mutations in MPZ probably generate the widest variety of 
65 
CMT phenotypes, ranging from mild CMT 1 B to more severe DSS, CH or 
even CMT 2 (Fig. 1.10). This variety in CMT phenotypes is paralleled by 
a great diversity in pathological traits, including demyelination, 
dysmyelination, tomacula, myelin outfolding or axonal loss with clusters 
of regenerating axons. These different phenotypes indicate different 
mutation-specific pathogenetic mechanisms that can be investigated in 
animal models. 
In contrast to PMP22, there are no naturally occumng mouse 
mutants with Mpz point mutations. In the last decade, mice have been 
engineered in order to introduce specific PO mutations and produce both 
Loss-of-Function (LoF) and Gain-of-Function (GoF) models of MPZ-
related neuropathies. 
1.9.2.1 LoF Mouse models: knock-out mice for PO have been 
generated using homologous recombination in embryonic stem cells to 
replace the endogenous PO gene on mouse chromosome 1 with an 
inactivated PO gene (Giese et aI., 1992). Heterozygous null mice develop a 
late-onset neuropathy. The myelin sheaths of PO+I- mice were 
indistinguishable from those of PO+I+ mice until four months of age, when 
mild hypomyelinated profiles appeared and occasional onion bulbs were 
indentified. These morphological abnormalities were more evident in one-
year-old animals: segmental demyelination and formation of onion bulbs 
become predominant pathological features in peripheral nerves, resulting 
in moderate electrophysiological alterations (significant increase III 
compound muscle action potential latencies; Martini et aI., 1995). In 
contrast, homozygous-null mice showed a very early-onset neuropathy: 
when the mice were two-weeks old they presented a phenotype 
characterized by weak vibrations of the animal body; four-week old 
mutants developed clasping of hindlimbs when lifted by the tail, slight 
tremors and jerky movements of the hindlimbs; with age, this behaviour 
became more pronounced and some of the animals developed convulsions. 
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Fig. 1.10: Mutations in the open reading frame of MPZ, which are associated with early 
onset or late onset symptoms of neuropathy. Early onset cases are defIned as those with a 
delayed onset of walking or other early milestones. Late onset cases are defmed as those 
with their fIrst symptoms of neuropathy after age 21. (This fIgure is taken from Shy et aI., 
2004). 
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Their peripheral nerves showed severe morphological abnormalities such 
as myelin uncompaction and an unusually high number of non-myelinated 
axons, already apparent four days after birth. With age, hypomyelination 
became even more severe, with poorly compacted myelin sheaths, some 
axons surrounded by reduced or absent wraps of SC membrane, redundant 
basal lamina and formation of rudimentary onion bulbs (Giese et aI., 1992; 
Maliini et aI., 1995). Finally, homozygous-null mice develop a distal 
axonopathy with significant loss of distal axons (Frei et aI., 1999) These 
severe morphological alterations in PO-/- mice are reflected by 
dramatically reduced nerve conduction velocities (Zielasek et aI., 1996). 
These two situations model one MPZ mutation, V I 02FS, which 
probably represents a complete null allele; the mutated protein is predicted 
to contain only 78 aminoacidic residues, with no transmembrane domain 
(Pareyson et aI., 1999; Warner et aI., 1996). However, in an extended 
family, a phenotype in the heterozygous state was recognized only after 
homozygous children presented with DSS. The children presented delayed 
motor milestones, severe weakness and NCV < 4 mls. Subsequent nerve 
biopsies showed severely reduced numbers of myelinated fibers, 
abnormally thin myelin sheaths and numerous basal lamina onion bulbs. 
Heterozygous relatives were asymptomatic, with only a very modest 
reduction in NCV (Sghirlanzoni et aI., 1992). 
1.9.2.2 GoF Mouse models: from the studies presented in the 
previous paragraph, it seems clear that complete haploinsufficience of PO 
both in human and mouse could result only in a mild neuropathy; as a 
consequence, many MPZ-related neuropathies probably include an 
additional gain of abnormal functional that could arise from either: 
1) a dominant-negative effect that originates from the myelin 
sheath or, 
2) a toxic effect of the mutant protein that initiates from an 
intracellular location during the synthesis and trafficking of PO. 
Support for the notion of gain of function comes from different 
evidence, in vitro experiments and transgenic mice. In human samples, 
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high magnification electron microscopical analyses of CMT patient nerve 
biopsies showed that peripheral demyelinating neuropathies have 
distinguishable ultrastructural phenotypes that depend on the alteration in 
primary structure of PO; this suggests that patients with PO mutations 
could express the mutated abnormal protein that is inserted into the myelin 
sheath where it could lead to specific impairments in inter-membrane 
appositioning (Kirshner et aI., 1996). In addition, in vitro coexpression of 
full-length PO and mutated PO (missing either 52 or 59 aminoacids from 
the cytoplasmic domain) in ClIO cells, prevents the full-length PO protein 
from behaving as an adhesion molecule; this shows that the mutated fonns 
of PO can have a dominant-negative effect on the adhesiveness of the WT 
protein (Wong and Filbin, 1996). 
Further evidence for gain of function of PO mutations come from 
transgenic mice (Wrabetz et aI., 2000; Previtali et aI., 2000; Wrabetz et aI., 
2006). To test for GoF mechanisms, several MPZ mutations have been 
inserted into the Mpz gene, which was then inserted as a random trangene 
in the mouse genome, in addition to the two endogenous Afpz alleles. In 
this way loss of mutant PO function in these mice should not be visible. As 
a preliminary control for this kind of approach, additional copies of wild-
type Mpz have been inserted randomly in the mouse genome. The analysis 
of these transgenic mice showed that normal peripheral nerve myelination 
depends on strict dosage of Mpz (Wrabetz et aI., 2000). The mice in fact 
manifested a dose-dependent, dysmyelinating neuropathy, ranging from 
transient perinatal hypomyelination to arrested myelination and impaired 
sorting ofaxons by Schwann cells. Such defects represent a gain of 
normal PO function and could be associated with premature arrival of PO 
in the membrane spiraling around the axon (= inner mesaxon; Yin et aI., 
2000). Myelination was restored by breeding the trans gene into the Mpz-
null background, demonstrating that dysmyelination does not result from a 
structural alteration or Schwann cell-extrinsic effect, but only to PO 
glycoprotein overexpression. Mpz mRNA overexpression inthe transgenic 
animals ranged from 30-700%. Breeding experiments placed the threshold 
for dysmyelination between 30 and 80% Mpz overexpression. 
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Following on these studies, we have investigated gain of abnonnal 
function in authentic mouse models of CMTI B mutations. S63 (34th 
residue of MPZ, after cleavage of the signal peptide) is conserved from 
fish to human (Kirschner et a1., 2004), and mutations of S63 in the POECD 
detennine diverse neuropathy phenotypes. Lupski and colleagues (Warner 
et a1., 1996) proposed that PO deleted for S63 (POS63del) and associated in 
humans with CMTI B phenotype (Kulkens et aI., 1993) would be unstable, 
resulting in the loss of one-half of PO function, whereas substitution of 
serine to cysteine (POS63S), associated with Dejerine-Sottas syndrome in 
humans (Hayasaka et a1., 1993) might produce aggregates and a toxic gain 
of function in the myelin sheath. To test this hypothesis, we produced 
transgenic mouse models expressing the mutated alleles, using the same 
approach as for Mpz overexpression (a random trangene inserted in the 
mouse genome, in addition to the two endogenous Mpz alleles, in a way 
that only phenotypes resulting from gain of function can be observed). 
Both S63del and S63C mice develop neuropathies that resemble the 
corresponding human neuropathy. Each P063 mutant acts via gain of 
abnonnal function, but their pathogenetic mechanisms originate from 
different intracellular locations. S63C arrives to the myelin sheath where it 
produces a packing defect, whereas S63del is retained in the ER and 
induces an Unfolded Protein Response (UPR), probably toxic to the 
myelin-fonning Schwann cell. Interestingly, this was the first evidence for 
UPR associated with peripheral neuropathies (Wrabetz et a1., 2006). 
In this thesis, I describe the generation and characterization of one 
authentic mouse model of an HMSN mutation, associated in humans with 
the most severe phenotype resulting from MPZ mutations, the Congenital 
Hypomyelination Neuropathy. Thus, to generate this authentic model, we 
decided to use homologous recombination in ES cells in order to replace 
one mouse endogenous Mpz allele, with one human MPZ allele, carrying 
the specific mutation in its open reading frame. This mutation is a C to T 
transition in exon 5 that, once translated, generates a premature stop codon 
in the cytoplasmic domain of PO. Our additional hope then is that the 
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characterization of this mouse model could give more indication of the 
role of the PO cytoplasmic tail in peripheral nerve myelination. 
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2. RESULTS 
The purpose of this thesis is to describe and discuss the creation and 
characterization of a new transgenic mouse model of POQ215X mutation 
associated with Congenital Hypomyelination neuropathy in humans. 
2.1 Patients carrying POQ215X mutation 
In 1996, Warner et al. described a patient that presented early in 
life (10 months of age) with delayed motor milestones and severely 
reduced nerve conduction velocity (= NCV, 6 mls), indicative of a 
generalized demyelinating peripheral neuropathy. A sural nerve biopsy 
was performed 8 months later and revealed abnormally thin myelin 
sheaths with a mild reduction of the number of myelinated fibers; no 
axonal degeneration was visible and no macrophages could be observed. 
Rare rudimentary onion bulbs were seen. Occasionally, large axons were 
found that had no myelin and were surrounded by Schwann cells with 
abundant cytoplasm. All these morphological defects were more indicative 
of an abnormal development of myelin rather than the result of a failed 
remyelination process, following demyelination. For this reason the 
patient was diagnosed with a Congenital Hypomyelination. The patient 
was then examined at 6 and 8 years of age and nerve conduction velocity 
confirmed the previous findings. 
Heteroduplex analysis of the patient highlighted the presence of a 
base change in exon 5 of the MPZ gene, a C to T transition at nucleotide 
643 that creates a premature stop in the GIn 215 codon (numbering 
includes 29-residue leader sequence). Further analyses indicated that the 
mutation was a de novo mutation, not inherited from one of the parents, 
and that it was a disease-associated mutation. 
Another patient, carrying the same de novo mutation in the MPZ 
gene was then described (Mandich et aI., 1999); the patient was 12 months 
old when she was first evaluated by a neurologist because of delayed 
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motor milestones; the neurological examination revealed diffuse muscle 
weakness, hypotonia, reduced deep tendon reflexes, scoliosis and foot 
deformities (pes planus). NCVs at that age were absent. At 7 years of age, 
the patient confirmed the reported symptoms and manifested in addition 
sensory ataxia and distal muscle wasting of the lower limbs. Nerve 
conduction velocities reached a value of approximately 4 mls and sensory 
nerve action potentials were not recordable. A sural nerve biopsy 
confimed the pathological findings described in the previous patient by 
Warner: loss of myelinated fibers, hypomyelination of all the remaining 
sheaths, several completely unmyelinated axons frequently surrounded by 
Schwann cells with copious cytoplasm and, finally, atypical onion bulbs. 
2.2 Generation ofMpz Q215X1+ mice 
To express the Q215X mutated MPZ in mice, we generated a 
targeting vector (Fig. 2.IA), which contains the whole Alpz gene, except 
for the 5' untranslated region, exon I and part of intron 2. This targeting 
vector carries the C to T mutation in exon 5 and a neomycin gene 
expression cassette, for selection, inserted in intron 5 and flanked by two 
LoxP sites. The linearized vector was electroporated into TBV2 129SVPas 
embryonic stem (ES) cells and one potential recombinant was identified 
among 168 G418 selected clones, using a Southern blot assay, with a 
hybridization probe 5' to the targeting construct. As expected for a 
homologous recombination event, the endogenous Hind III fragment was 
larger by 1.3kb, due to the presence of the neomycin inse11ion (Fig. 2.1 B). 
We confirmed the absence of potential concatemers at the PO locus using 
two different probes inside the targeting vector, in order to evaluate for 
concatamer junction fragments in Southern Blot analysis (data not shown). 
The C to T transition in exon 5 results in the ablation of a restriction site 
for BsoF! endonuclease. To confirm the presence of the Q215X mutation 
in the genomic DNA of the ES clone, we amplified by PCR the genomic 
region flanking the mutation and we digested it with BsoF!. Restriction 
enzyme digestion revealed the expected absence of the BsoF! site in the 
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peR amplimer (Fig. 2.1 e). Targeted ES cells were injected into e57B1I6 
blastocysts and one germline male chimera transmitted the mutation to the 
offspring. We obtained mice carrying the Q215X NEO allele (Fig. 2.1A); 
these mice were then crossed with mice expressing eRE recombinase 
ubiquitously, to excise the neomycin selection cassette and we obtained 
mice having the Q215X mutated allele, which still carries one Lox P site 
in intron 5 (Fig. 2.1A). 
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Fig 2.1: A) Schematic representation of the genomic organization of wild-type, 
Q215XNEO and Q215X Mpz alleles. The external probe used for Southern Blot analyses 
of ES cell clones is indicated (E.P.), together with the length of the DNA fragments, 
originating upon Hindill digestion. The C to T mutation in exon 5 is indicated by 
asterisks. The BsoFI site within exon 5 is indicated (B). 
B) Southern Blot analysis of the genomic DNA of the ES cell clone where homologous 
recombination occurred. 
C) BsoFI restriction enzyme digestion of the PCR-amplified genomic region flanking the 
C to T mutation in ex on 5. The BsoFI site within exon 5 is indicated (B). 
75 
2.3 Expression and synthesis of Q215X MPZ 
We next studied the expression of the mutant allele. The Q2l5X 
mutation in MPZ is predicted to code for a truncated PO, lacking the C-
terminal 33 aminoacids of its intracellular domain. Western blot analysis 
performed on protein extracts from sciatic nerves of P28 wild type, 
Q2l5X heterozygous and homozygous mice confirmed that the mutation 
produces a smaller PO glycoprotein with a molecular weight of 
approximately 24kD (Fig. 2.2A). As shown in Fig. 2.2A, an additional 
band appears in the western blot for PO (indicated with an asterisk in Fig. 
2.2A); its putative molecular weight is approximately 27kD. This band 
could be the result of the secondary antibody reacting with other 
immunoglobulin-like chains present in the nerve, due to the fact that the 
same band is not always appearing, when performing western blot using 
the same antibody (= mouse mAbs P07, generous gift of Dr. Juan 
Archelos, Department of Neurology, Karl-Franzens-Universitat, Graz, 
Austria; Archelos et al. 1993) (see also Fig 2.11). Alternatively, this 
intermediate band could represent an intermediate product of PO 
glycosylation. 
Then, we quantitated the amount of the mutated protein relative to 
endogenous PO, using a densitometric approach, and we found it to be 10 
times less abundant than the endogenous one (ratio of approximately 
1: 1 0). Of note that the amount of protein extract loaded on each lane was 
normalized using p-Tubulin as a reference (Fig. 2.2A). 
Thus, in order to understand if this reduction in protein amount 
was determined at the level of transcription or translation, we performed 
an RT-PCR analysis on RNA from P28 sciatic nerves of wild type, Q215X 
heterozygous and homozygous mice. We amplified the mutated region 
with primers that recognized ex on 4 and 6 of Mpz, flanking the point 
mutation in exon 5 and we could distinguish and quantitate the Q215X 
mutated transcript relative to endogenous PO mRNA, after digestion with 
BsoFI restriction enzyme. As shown in Fig 2.28, this analysis indicated 
that the amount of transcript deriving from the mutated allele is 
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significantly lower (about 1 :20) than the amount of transcript deriving 
from wild type Mpz allele, indicating that very likely the reduction in 
protein amount could be due to reduced steady state levels of mRNA. 
Notably, this reduction in the total amount of PO mRNA is even more 
pronounced in the Q215X homozygous mice, where the amount of the 
mutated mRNA is less than double the levels ofQ215X mutated transcript 
present in the heterozygous state. 
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Fig 2.2: A) PO Western Blot analysis on protein extracts from sciatic nerves of wild type, 
Q215X1+ and Q215X1Q215X sacrificed at postnatal day 28. Normalization has been 
performed using ~ Tubulin as reference. The asterisk indicates an additional band 
appearing in the western blot for PO with a putative molecular weight of approximately 
27kD. 
B) BsoFI restriction enzyme digestion of the RT-PCR-amplified eDNA, obtained RNA 
extracted from wild type, Q215X1+ and Q215X1Q215X P28 sciatic nerves. The BsoFI 
sites within the amplified cDNA are indicated (B). 
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2.4 Effect of the LoxP site in intron 5 on MPZ expression 
This reduction in PO mRNA steady state levels could be due to a 
specific effect of the point mutation. Alternatively, the LoxP site left in 
intron 5 of the Q215X allele could reduce the PO mRNA and, as a 
consequence, result in an hypomorphic allele. To discriminate between 
these possibilities, we generated, by homologous recombination in ES 
cells, a control mouse (LoxP mouse), that carries the LoxP site in intron 5, 
but not the Q215X mutation in exon 5. We then produced hybrid LoxP 
mice with C57Bl6 outcrosses and we measured the expression of the allele 
by RT-PCR on RNA from sciatic nerves. We used primers in exons 2 and 
3 of Mpz that flank a polymorphic restriction site in exon 3, present only 
in the C57BI6 background, to quantitate the transcript deriving from the 
LoxP (l29SV background) allele relative to the one deriving from 
endogenous C57BI6 Mpz allele: we found a ratio of about 1:5 (Fig. 2.3). 
This indicated that the LoxP site has an effect on PO mRNA stability, but 
this effect could not account completely for the severe reduction in Q215X 
MPZ amount (1110 of endogenous PO). 
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2.5 Q215X1+ mice develop transient Congenital Hypomyelination 
Since the Q21SX mutation in human is autosomal dominant, we 
focused our phenotypical and morphological analyses on Q21SX 
heterozygous mice. Surprisingly, although the phenotype in the patients 
has a very early onset and is remarkably severe, heterozygous mutant mice 
did not present any external sign of peripheral neuropathy (gait difficulty, 
reduced weight, tremor, atrophy of the paraspinal and hindlimb 
musculature). As shown in Fig. 2.4 (M-N-O), semi-thin section analysis of 
P28 sciatic nerves from Q2ISX heterozygous mice revealed only a mild 
hypomyelination, not consistent with the severe dysmyelinating 
neuropathy described in the patients. Thus, we analyzed the morphology 
of sciatic nerves in the first two weeks of postnatal life. During this period, 
when myelination takes place, PO glycoprotein expression is induced at 
very high levels in myelin-forming Schwann cells. Sciatic nerves of PI 
and PS mutant mice did not show any obvious abnormality, when 
compared to wild type littermates (Fig. 2.4A to 2.4F). In contrast, at P11, 
some bundles of unsorted mixed calibre axons were present in Q21SX 
heterozygous mice (Fig. 2.4H-arrowheads), and not in wild type 
littennates (Fig. 2.41) or in PO haploinsufficient mice (Fig. 2.4G). At PI4, 
these radial sorting defects were not visible anymore indicating that the 
myelination deficit observed in P 11 Q21SX heterozygous mice is 
transient. 
In order to confirm and characterize the radial sorting defects, we 
decided to study bundles of wt, POKO +1- and Q21SXI+ Pll nerves by 
electron microscopy (Fig. 2.S). In all the nerves we analyzed, the bundles 
are surrounded by Schwann cells, with normal basal lamina and include 
mixed calibre axons, with diameters ranging approximately from 0.2 to 2 
~lm. In most of the bundles, surrounding SCs send their cytoplasmic 
processes within bundles, sorting single axons away from contact with 
their neighbours. 
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Fig 2.4: Semi-Thin Sections of sciatic nerves taken from wild type, Q2ISx/+ and POKO 
+1- mice, at PI (A-B-C), PS (D-E-F), Pll (G-H-I), P14 (J-K-L) and P28 (M-N-O). In 
H, arrowheads indicate bundles of unsorted axons. Magnification lOOX. 
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P1 
Fig 2.5: Electromicrographs of sciatic nerves taken from wild type, Q215X1+ and POKO 
+/- mice at PII , showing details of bundles of unsorted axons. Magnification 20000X. 
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To quantitate these abnonnalities, we used the NIH Image J 
software: first, we perfonned detailed morphometric analyses to look at 
the distribution of fiber diameters in unsOlied bundles. As shown in Fig. 
2.6, bundles from wt (in total 24 from n=3 mice) and POKO +1- (in total 23 
from n=3 mice) nerves at PII contain none or few axons with diameter < 
I)lm (the maximum diameter they reach being < 1.2)lm), whereas bundles 
from Q215X1+ animals (in total 34 from n=3 mice) include axons with 
diameters larger than I.4)lm (the maximum diameter they reach being 
approximately 2.2)lm). In addition, we counted the total number ofaxons 
present in the bundles; as shown in Fig. 2.7A, our analysis revealed that 
the Q215X heterozygous mice present a higher, although not to a 
significant extent, number ofaxons in the bundles (indicated by asterisks 
in Fig 2.7A); secondly, we examined the number of unsorted axons (an 
unsorted axon being in direct contact with other axons and not surrounded 
only by SC processes; indicated by asterisks in Fig. 2.7B) and we found it 
significantly higher in Q215X1+, as compared to both wild type and POKO 
heterozygous mice. Third, we also counted the number of sorted (not in 
close contact with other axons, but surrounded exclusively by SC 
processes, indicated by asterisks in Fig. 2.7C) and unsorted axons 
(indicated by asterisks in Fig. 2.7D) present within the bundles and having 
a diameter greater than 1 )lm; by this age (P 11), in fact, every large calibre 
axon in a nonnal nerve has already been segregated and presents at least 
some turns of compact myelin. As shown by the graphs, both parameters 
are significantly higher in the Q215X1+ than in the other two genotypes 
examined; in fact, while in control nerves all the axons larger than l)lm in 
diameter had been already segregated and at least partially myelinated, in 
contrast, approximately 15% of the axons we measured in the bundles of 
mutant Q215X1+ mice had a diameter ranging from I to 2 )lm (Fig. 2.6). 
Taken together, these data showed that Q2I5X heterozygous mutant mice 
present a transient dysmyelinating neuropathy, due to a radial sorting 
defect that appears around PIO and that disappears around P14, leading to 
a delay in the myelination process. Since we have already demonstrated 
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that in Q215X heterozygous mutant mice the amount of the mutated 
protein relative to endogenous PO was 10 times less abundant, one can 
argue that the transient phenotype we described could be the result of an 
overall reduction of the total amount of PO glycoprotein in Q215X 
heterozygous mutant mice. Nevertheless, our morphological analysis 
demonstrated that the radial sorting defect observed in Q215X 
heterozygous mutants is specifically due to the presence of the Q215X 
mutated glycoprotein and not to the lower amount of MPZ in mutant mice. 
This is clearly demonstrated by the absence of similar unsorted bundles of 
large calibre axons in PO null heterozygous mice; in POKO +1- mice in fact 
the amount of total PO mRNA is lower than in Q215X heterozygous mice. 
This absence demonstrates that the Q215X point mutation acts through a 
gain of function mechanism. 
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the total number ofaxons examined/genotype. 
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Fig 2.7: A) Total number ofaxons within the bundles (sorted + unsorted). Error bars 
represent SEM. 
B) number of unsorted axons (in direct contact with other axons, indicated by asterisks in 
the right panel) within the bundles. 
C) number of sorted axons (not in close contact with other axons, but surrounded by SC 
processes, indicated by asterisks in the right panel) within the bundles, with a diameter > 
Il-lm. 
D) number of unsorted axons (in direct contact with other axons, indicated by asterisks in 
the right panel) within the bundles, with a diameter > 111m. 
*p<O.05; **p<O.Ol; ***p<O.OOI vs. wild type (one-way ANOVA followed by Tukey 
test) 
#p<O.05; ##p<O.OI; ###p<O.OOI vs. POKO+/- (one-way ANOVA followed by Fisher test) 
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2.6 Q215X1+ mice present a neuromuscular defect 
We next tested if this transient defect in the process of myelination 
resulted in a developmental motor deficit, by rotarod test, a behavioural 
test already used in the past in Dr. Wrabetz's lab to assess motor 
coordination in mice. Mutant and wild type mice, from PlO to P12, were 
placed on a horizontal rod, rotating at increasing speed and the time they 
remained on the bar was measured and plotted. The purpose of the rotarod 
test is to assess the mice sensorimotor coordination. The test is sensitive to 
damages (traumatic, drug induced or genetic) that effect motor function. 
After the first two trials, where the difference between control and mutant 
mice is not significant, Q215X heterozygous mice remained on the bar for 
significantly less time than control mice, revealing that the radial sorting 
defects observed in sciatic nerves result in a motor deficit in P 11 mutant 
mice (Fig. 2.8). The motor deficit is no longer present in adult (P28) mice 
(data not shown). 
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Fig 2.8: Rotarod analysis shows that Q215X1+ mice at PI1 (n=72) remain on the 
accelerating cylinder less time than the wild type littermates (n=57). Error bars represent 
SEM. *p<O.05; **p<O.OI vs. wild type (t-test) 
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2.7 PO Q215X MPZ is not trafficked correctly 
Genetic and expressIOn analysis of Q215X1+ together with 
morphological analyses of the mouse sciatic nerves, suggest a gain of 
abnormal function, resulting from the truncated Q215X MPZ. Thus, as a 
further step to characterize our mouse model, we decided to investigate the 
pathogenetic mechanism through which the mutated protein is able to 
produce the aberrant phenotype. We began by determining the 
intracellular location of the Q215X MPZ, in order to strengthen our 
previous hypothesis that the transient phenotype we observed in our 
mutant mice might be determined by an improper trafficking of PO 
Q215X. To this end, we bred the mutation to obtain Q215X homozygous 
mice, in which only the mutated protein is detectable. As shown in figure 
2.9A and B, semi-thin sections of these nerves, at P28, revealed a 
substantial hypomyelination, with the presence of many fibers with thin 
myelin sheaths for the diameter ofaxons, and few fibers in which single 
Schwann cells ensheathed axons, but were not able to form any myelin 
sheath around them. Then, we stained transverse sections of sciatic nerves 
from P28 homozygous mutant and control mice, using an antibody 
directed against the extracellular domain of PO. To localize intracellularly 
the mutated MPZ, we co-stained the sections with an antibody that 
recognizes the KDEL signal, a tetrapeptide located at the carboxy-terminal 
sequences of Endoplasmic Reticulum (= ER) luminal proteins, that 
perform essential functions related to protein folding as well as assembly. 
In control nerves (Fig. 2.10 A-B-C), almost all PO glycoprotein was 
detected in compact myelin and its signal never co-localized with ER 
resident proteins. In contrast, in homozygous mutant mice (Fig. 2.10 D-E-
F), Q215X truncated PO partially co-localized with anti KDEL antibody, 
indicating that the mutated protein is, at least in part, sequestered in the 
ER. 
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Fig 2.9: Semi-Thin Sections of sciatic nerves taken from wild type (A) and 
Q215X1Q215X (B) mice at P28. Magnification loOX. 
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Fig 2.10: Immunofluorescence staining for PO (A,D) or KDEL (B, E) or overlay of the 
two (e, F) in WT (A, B, C) and Q215X1Q215X (D, E, F) sciatic nerves at P28. PO and 
KDEL stainings were almost mutually exclusive in wild-type nerves, with most PO 
staining in circular myelin sheaths. In contrast, a part of PO and KDEL staining coincided 
in Q215X1Q215X nerves (see asterisks). Magnification lOOX. 
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In addition to the immunohistochemical analyses, to further 
characterize the intracellular location of the mutant protein, we analyzed 
the glycosylation of Q215X PO, using a specific glycosidase digestion 
approach. As already mentioned in the introduction, PO is nonnally 
glycosylated within the Schwann cell ER, at the level ofNl22 (D'Urso et 
aI., 1990). In the pre-Golgi and cis-Golgi compartments, N-linked 
glycoproteins contain immature high-mannose oligosaccharides that are 
sensitive to digestion with endoglycosidase H (EndoH). When the proteins 
arrive at the medial-Golgi compatment, oligosaccharides are processed to 
mature, becoming resistant to EndoH digestion. Both EndoH-resistant and 
EndoH-sensitive PO have been found in nonnal myelin sheaths (Brunden, 
.1992). Another specific glycosidase, peptide N-glycosidase F (PNGaseF), 
is able to digest N-linked oligosaccharides, despite their maturation. After 
EndoH or PNGaseF digestion, Western Blot analysis of mutant nerve 
, 
protein lysates demonstrated that our cytoplasmic tail truncated PO is 
mostly glycosylated; nevertheless a small fraction of it is EndoH resistant 
(indicated by a red arrow in Fig. 2.11). Thus, most of PO Q215X has 
immature glycosylation, which could be consistent with ER or Golgi 
localization, but some may arrive to the myelin sheath. 
Of note that, in this western blot analysis no additional band for PO 
with an approximate molecular weight of 27kD appears, even when 
endoglycosidase digestion occurred. This demonstrates that this 
intennediate band could not represent an intennediate product of PO 
glycosylation, but it is very likely the result of the secondary antibody 
reacting with other immunoglobulin-like chains present in the nerve. 
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Fig. 2.11: Biochemical and expression analysis of Q2 l5X mutants shows that the 
mutated PO has altered post-translational modification. 
Western analysis for PO on sciatic nerve lysates from WT or Q2 l 5X homozygous 
mutants untreated (C) or after digestion with EndoH (H) or PNGaseF (F) . 
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3. DISCUSSION 
In the result section of this thesis the creation and characterization of a 
new transgenic mouse model of POQ215X mutation associated with 
Congenital Hypomyelination neuropathy in humans was described. In this 
section, the obtined results will be discussed. 
3.1 Generation of Mpz Q215X1+ mice, expression and synthesis of 
Q215X MPZ and effect of the LoxP site in intron 5 on MPZ 
expression 
As already discussed in the result section, taking advantage of 
homologous recombination in ES cells and electroporating them into 
mouse blastocists, we obtained mice carrying the Q215X NEO allele (Fig. 
2.IA) that were then crossed with mice expressing CRE recombinase 
ubiquitously, to excise the neomycin selection cassette in order to generate 
mice having the Q215X mutated allele and carrying one Lox P site in 
intron 5 (Fig. 2.1A). We then studied the expression of the mutant allele. 
We have shown that the Q215X mutation in MPZ produces a smaller PO 
glycoprotein with a molecular weight of approximately 24kD (Fig. 2.2A). 
Since both Warner and colleagues and Mandich and her collaborators did 
not examine their patient biopsies for the presence of a truncated form of 
PO, lacking part of its intracellular domain, this is the first demonstration 
that the C to T transition in exon 5 of Mpz gene observed in the two 
different patients effectively results in a shorter form of PO glycoprotein, 
with a lower molecular weight, as compared to wild type protein. 
Then, we quantitated the amount of the mutated protein relative to 
the the endogenous PO and we found it to be 10 times less abundant than 
the endogenous one (ratio of approximately 1:10 - Fig. 2.2A). By RT-PCR 
analyses we then demonstrated that very likely the reduction in protein 
amount could be due to reduced steady state levels of mRNA in mutant 
mice. In addition, we generated and characterized a control LoxP mouse 
carrying the LoxP site in intron 5, but not the Q215X mutation in exon 5. 
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We then measured the expression of the LoxP allele by RT-PCR on RNA 
from sciatic nerves, relative to the one deriving from endogenous C57Bl6 
Mpz allele (Fig. 2.3). We demonstrated that the LoxP site has an effect on 
PO mRNA stability, reducing it, but not to the same extent as for Q215X 
MPZ allele. Interestingly, such an effect of the LoxP insertion on mRNA 
steady state levels was never reported before. Therefore, the mechanism 
by which LoxP reduces mRNA levels is not clear. Of note that intron 5, 
the one bearing the LoxP site in the mutated Mpz allele, is very short, only 
107bp in length. It is well known that the process of transcription is slow 
and, at least for highly expressed genes, transcription of long introns, 
particularly common in mammals, is expensive. As a consequence, it has 
been demonstrated that introns in highly expressed genes are shOlter than 
those in genes that are expressed at low levels, and natural selection 
appears to favour short introns in highly expressed genes to minimize the 
cost of transcription and splicing (Castillo-Davis et aI., 2002). In order to 
express the Q215X mutated MPZ in vivo, we generated mice having the 
Q215X mutated allele, carrying one Lox P site in intron 5; this means that 
an original intron of 107 bp has reached the "new" length of 
approximately 220bp. Such an increase in intron length could explain the 
less efficient transcription of the mutated Mpz allele in the LoxP mouse, 
but at the same time it may not be the only reason for the massive 
reduction of Q215X mutated transcript. One possible explanation for this 
further decrease in Q215X mRNA is Nonsense-Mediated Decay; it is 
known in fact that the strength of biological systems depends on the 
function of proofreading mechanisms preventing errors. Studies in yeast 
(Losson and Lacroute, 1979) and of human genetic disorders (Chang and 
Kan, 1979) allowed the identification of a conserved control mechanism 
that identifies faulty open reading frames and eliminates imperfect 
mRNAs that contain premature translation termination codons (PTCs) and 
code for nonfunctional or dangerous polypeptides; this mechanism has 
been termed nonsense-mediated mRNA decay (NMD) (Hentze and 
Kulozik, 1999). Anyhow, the hypothesis that NMD may be responsible for 
the reduction of Q215X mRNA is not supported by the position of the 
PTC in the Q215X mutated allele; it is well known in fact that the 
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distinction between a nonnal and a premature stop codon is made on the 
basis of its location with respect to the last exon-exon junction: in 
particular, the tennination codon is considered premature when it is 
positioned > 50-55 nucleotides upstream of the last exon-exon junction 
(Nagy and Maquat, 1998). Here the Q215X mutation is only 3 nucleotides 
from the last exon-exon junction. In addition to that, recent data 
demonstrated that NMD could be one of the molecular mechanisms by 
which different mutations, in particular truncating mutations, in the same 
gene can result in different disease phenotypes; in particular, the more 
severe phenotypes occur only when the mutated mRNAs are able to 
escape NMD (Inoue et aI., 2004). The authors focused their attention on 
SOX 10 and MPZ mRNA containing PTCs: mutant mRNAs that result in 
a less severe disease have decreased stability, while the more severe 
neurological diseases seem to result from a stable mRNA that is translated 
into a mutant protein with potent dominant-negative activity. More 
specifically the authors tested several MPZ mutated transcripts (Produced 
in trasfected human cell lines) and found that the PTCs associated with 
severe diseases are all located in the last exon (except for one, Q215X, 
that is located at the distal end of the penultimate exon) and resulted in an 
accumulation of mRNA at levels equivalent to the wild-type allele. Since 
no expression data are available from Q215X human patient samples, our 
mutant mouse could be useful to confirm in vivo these in vitro findings 
and could help in clarifying the mechanisms that are responsible for the 
massive reduction of Q215X mutated transcript. For instance, we can test 
Q215X sensitivity to NMD in mouse SN by treating excised and 
desheathed SNs with cycloheximide (CHX) in culture medium. CHX is an 
inhibitor of protein biosynthesis in eukaryotic organisms, produced by the 
bacterium Streptomyces griseus. As a positive control we can use SNs 
from a mouse line, generated in the lab and expressing an Mpz transgene 
containing lac-z and a premature stop codon, more than 50-55 nucleotides 
upstream of the last exon-exon junction and therefore predicted to undergo 
NMD. After CHX treatment, mRNA can be extracted and retro-
transcribed and expression evaluated by RT-PCR. If no difference in 
Q215X and LoxP-WT expression is detected after treatment, while, as 
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expected, there is a significant increase in the positive control, we could 
confinn that, also in vivo in a myelin context, Q215X does not undergo 
NMD. 
Other potential mechanisms through which LoxP could negatively 
influence expression can act both at the transcriptional or post-
transcriptional level. In fact, the LoxP-dependant expression reduction 
could be due to an effect of LoxP at the transcriptional level. Intronic 
sequences are known to be involved in transcriptional regulation and 
highly conserved sequences in Mpz intron 1 have previously been 
demonstrated to bind Sox 1 0 and Egr2 transcription factors (TF) and that 
this binding plays a key role in Mpz expression (LeBlanc et al., 2006). As 
already discussed, Mpz intron 5, where the LoxP site is inserted, is very 
short and highly conserved; there is the possibility to investigate potential 
TF binding sites, using the rVIST A software analysis and having intron 1 
binding as positive control. Last year, a sequence in mpz intron 5 has been 
identified as a potential binding site for CTCF, the vertebrate insulator 
protein (Kim et al., 2007). Interference with this binding could affect the 
euchromatinlheterochromatin status of the genomic region and thus alter 
the expression of mpz in our mice; we therefore can test by ChIP if CTCF 
does bind to Mpz intron 5 and if yes, ask in vivo in our LoxP control 
mouse if the presence of LoxP in intron 5 is able to abolish such binding. 
Recently in Dr. Wrabetz's lab Q215X heterozygous mice have 
been brought into the C57 background; as a consequence, the mpz 
expression in Q215X heterozygous mice has been re-evaluated in relation 
to the WT allele, using semiquantitative radioactive RT-PCR and taking 
advantage of a OpnII restriction site present in the background strain allele 
(C57) and absent in the ES cell strain (Sv129), used for the generation of 
our transgene. Transgene expression in the line carrying the mutation 
(Q215X) and in the one carrying only the LoxP site was 1:4 compared to 
the WT allele, indicating that the mutation itself was not able to induce 
any reduction in PO mRNA (Fig. 3.1). Interestingly, when examining mpz 
expression in the Q215X line through BsoFI digestion, the expression was 
quantified as I: 15 compared to WT. There is the possibility that such a 
difference in results, when analyzing two different segments of the same 
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cDNA, could be due to the presence of alternative splicing products in the 
3' region of the gene, where LoxP and the mutation are inserted. In order 
to test this hypothesis, different RT-PCRs from sciatic nerve cDNA from 
Q215X homozygous, LoxP homozygous and WT animals using primers 
extending from mpz exons 4 and 5 to exon 6 can be perfonned and all the 
resulting amplimer patterns can be carefully analyzed and compared. The 
possibility of alternative splicing occurring in all the lines carrying the 
LoxP in intron 5 is further supported by the finding of a detailed 
bioinfonnatic analysis of the exon 6 splice acceptor perfonned in Dr. 
Wrabetz's lab; this analysis contributed to identify a "weak" splicing 
acceptor site in exon 6. The presence of the LoxP site and its flanking 
sequence between the mpz intron 5 branchpoint and the ex on 6 splice 
acceptor, along with the "weak" acceptor site in exon 6, may have 
contributed to the generation of these alternative splicing patterns. It's 
important to remark that the LoxP sequence, along with its flanking 
region, can function here as a cryptic splice acceptor (Fig. 3.2). 
Alternative splicing at the exon 5-6 junction could explain the 
difference amongst the expression results using the polymorphic DpnII 
site in exon 3 or the BsoFI restriction site in exon 5, but doesn't justify the 
overall underexpression of the mpz-IoxP alleles of 1:4 compared to WT 
mpz alleles. Increased instability of the alternatively spliced fonns could 
explain this reduction. To test this hypothesis, LoxP homozygote sciatic 
nerves can be explanted, desheathed from the perinevrium to make them 
more accessible to treatment, and incubated at 37 C in culture medium 
with RNA polymerase II inhibitor actinomycin D (ActD). RNA at 
different time-points (1-2-4 hours) can be extracted and RT-PCRs for mpz 
perfonned, to analyze the stability of the different splice variants. This 
approach will give us the possibility to evaluate the half-life of the 
alternatively spliced variants, if any, and their contribution to the overall 
mpz expression reduction. 
99 
FW 
86 
326qJ 
244qJ 
82qJ 
A B 
CR15X )( 86 )< 
LoxP/C57 $1' / / ex-CJl15X1C57 
.--A-
r ~ 
LoxPaQl15X 
-+ ---- - - -(129Sv) 
wr 
[pil 
-- -- -
_l... 
- -
(C57JB)) 
-------..--.--
326qJ 
Ql15X PO : v..t PO (dNA.) 
1:4 
LaxP PO : v..t PO 
1:4 
Fig. 3.1: A) DpnII restriction enzyme ctigestion of the RT -PCR-amplified cDNA, 
obtained from RNA extracted from wt (FVB/C57BI6 - left lane), Q215X1+ heterozygous 
(l29SVPas/C57B16 - mid lane) and LoxP/+ heterozygous (l29SVPas/C57Bl6 - right 
lane) P28 sciatic nerves. The DpnII site within the amplified cDNA is indicated. The red 
arrow indicates the amplified D A coming from the LoxP and Q215X Mpz alleles. 
B) Schematic representation of the genomic organization of LoxP and Q215X Mpz 
alleles. The Dpoll site within exon 3 is indicated, together with the primer pair used to 
amplify the cDNA from sciatic nerve of Q215X heterozygous, LoxP heterozygous and 
WT animals using primers extending from mpz exons 2 to exon 4. 
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Fig. 3.2: Mpz DNA sequence of exon 5, iutron 5 and exon 6 and LoxP site: the 
branchpoint, together with the BsrGI within intron 5, used to generate the Q215X allele, 
and the acceptor site within LoxP are indicated. 
3.2 Q215X1+ mice develop transient Congenital Hypomyelination 
As reported in the results, our phenotypical and morphological 
analyses on Q2I5X heterozygous mice revealed that heterozygous mutant 
mice present a transient dysmyelinating neuropathy, due to a radial sorting 
defect that appears around PI0 and disappears around P14, leading to a 
delay in the myelination process. Furthermore, we demonstrated that the 
radial sorting defect observed in Q215X heterozygous mutants is 
specifically due to the presence of the Q215X mutated glycoprotein and 
not to the lower amount of MPZ in mutant mice. Finally, by comparing 
morphological features of our Q215X heterozygous with the ones of 
POKO +/- mice, we clearly showed that the Q215X point mutation IS 
acting through a gain of function mechanism. 
What Gain of Function mechanism might explain the 
morphological phenotype we have observed in Q215X heterozygous 
animals? Analyses of mutant mice presenting similar phenotypes might be 
revealing. For example, one possible explanation for the transient 
dysmyelinating phenotype we observed in our mutant mice is that the 
protein, PO Q215X, can somehow interfere with laminin signals, necessary 
for Schwann cells to segregate the axons. In fact, an impairment in the 
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process of radial sorting has been first described in mice deficient for 
Laminin-2, the major laminin isofOlm within the PNS. The animals 
present bundles of unsorted axons in spinal roots and, to a minor extent, in 
sciatic nerves (Bradley and Jenkinson, 1973). A further hint into the 
regulation of radial sorting process came from the generation and 
characterization of mice undergoing Schwann cell specific inactivation of 
PI integrin; these mice develop a severe dysmyelinating phenotype, due to 
the inability of Schwann cells to form and maintain interactions with 
axons. In pl-integrin null animals, Schwann cells can migrate, proliferate 
and survive as in normal mice. Careful ultrastructural analysis of mutant 
nerves revealed that PI is necessary for Schwann cells to reorganize the 
cytoskeleton as they ensheath axons. In its absence, Schwann cells cannot 
segregate axons and leave bundles of naked axons in adult nerves (F eltri et 
aI., 2002). 
More recently, further data on engineered mIce led to the 
identification of two genes downstream of laminin signals, necessary for a 
correct spatial and temporal axonal sorting within peripheral nerves. One 
of these genes is Rac!. It is known that the levels of the small GTPase 
Rac1 activity control extension of radial lamellae in different cell types 
(Pankov et aI., 2005). Within the PNS, the segregation ofaxons by 
Schwann cells requires the activation of Rac 1 by PI integrin. It has been, 
in fact, demonstrated that cultured Schwann cells, devoid of pi-integrin, 
can migrate and elongate correctly on axons, but are not able to extend 
radial cytoplasmic processes; in addition, in PI null nerves the levels of 
active Rac-l are decreased; on the other hand, ectopic expression of active 
Rac1 in PI null nerves results in improvement of sorting defects. Finally, 
the generation and characterization of Rac I null mice showed a delayed 
axonal sorting within peripheral nerves (Nodari et aI., 2007; Benninger et 
aI., 2007). 
Despite the striking similarities, Rac1 null mice show milder radial 
sorting defects as compared to pi-integrin knock-out 'animals. This 
indicates that PI signalling in Schwann cells is not only acting via Rac 1. 
This finding is supported by the empirical data showing that pl-integrin is 
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able to physically associate to the nonreceptor tyrosine kinase F AK 
(Fernandez-Valle et aI., 1998). Moreover, when the FAK gene is 
specifically inactivated in SC, mutant nerves are characterized by alTested 
sorting of large-calibre axons. Of note is that mutant SC can infiltrate 
processes between axons, but are not able to proliferate properly, 
indicating that the dysmyelinating phenotype can be the result of an 
insufficient number of SC (Grove et aI., 2007). F AK is not the only gene 
whose ablation results in sorting defects, due to impaired SC proliferation; 
another example comes from cdc42 knock-out mice, where the radial 
sorting defects could be related to a lowered SC proliferation rate. In 
contrast to F AK, Cdc42 activation is not dependent on PI activity; in fact, 
the levels of active Cdc42 in 131 null nerves appear not to be substantially 
different to those of wildtype animals (Benninger et aI., 2007; Nodari et 
aI.,2007). 
In this section, we presented a new transgenic animal with a 
heterozygous mutation in the intracellular domain of MPZ that developed 
a transient congenital hypomyelination phenotype. This hypomyelinating 
phenotype is highly similar, even if to a less severe extent, to other 
hypomyelinating mice that carry mutation in different genes, all involved 
in the laminin signalling events, responsible for controlling the 
myelination process and the cross talk between the Schwann cell 
compartment and the nerve environment. These similarities lead me to 
suggest that PO Q215X could perturb events downstream of the laminin 
signalling pathways. This "laminin signalling pathway perturbation" 
hypothesis is further supported by in vitro findings, obtained in transfected 
MDCK cells (see paragraph 5.5). When these cells are stably transfected 
with PO glycoprotein, they localize PO within their basolateral surface; on 
the contrary, deletion of the PO cytoplasmic domain results in apical 
targeting in MDCK cells. Using the same in vitro approach, the authors 
identified a novel amino acidic sequence (=Y AML motif) within the PO 
cytoplasmic tail that includes active tyrosine-based and leucine-based 
signals and that is necessary for basolateral targeting of PO (Kidd et aI., 
2006). Further support to this hypothesis came already from previous 
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studies perfonned on transgenic mice overexpressing wild type PO 
glycoprotein. As we have seen in paragraph 1.9.2.2, these mice manifested 
a dysmyelinating neuropathy, that ranges from transient perinatal 
hypomyelination to arrested myelination and impaired sorting ofaxons by 
Schwann cells. Such defects have been associated with incorrect 
trafficking of PO in the SC membrane (Yin et aI., 2000). Thus, according 
to the data we collected, we can speculate that PO Q215X is not properly 
trafficked within Schwann cells. Perhaps, it arrives at an inappropriate 
location (e.g. the basal surface near the basal lamina), where it perturbs 
laminin signalling, somehow altering the communication between axons 
and Schwann cells and generating the transient radial s0l1ing phenotype 
we have described. This hypothesis could be tested using a strategy similar 
to the one used by Kidd et al. in 2006 and described later in section 2.7. 
An alternative possibility to explain the phenotype of Q215X 
heterozygous mice is suggested by the similarity to claw paw mice. In 
1991, the murine autosomal recessive mutation elaw paw was described: 
homozygous elp/clp mice presented abnonnalities of limb posture within 
the first one or two postnatal days; morphological analyses of elp/elp 
mutant sciatic nerves showed that affected animals present delayed and 
abnonnal myelination in the peripheral nervous system; in addition, the 
nerves presented defects in radial sorting of the fibers, with blocked 
myelination of small calibre axons, that are myelinated in nonnal animals 
(Henry et aI., 1991). The abnonnalities highlighted in clp/elp mice 
represent Schwann cell difficulties in perfOlming the transitional step from 
promyelin to compact myelin. A recent study, where reciprocal nerve 
grafting experiments between wild-type and clplclp animals were 
perfonned, demonstrated that the elp mutation affects the Schwann cell 
compartment and possibly also the neuronal compartment, being likely 
involved in direct axon/Schwann cell interactions. Furthennore, within the 
Schwann cell compatment, elp affects a myelin-related signaling pathway 
that regulates the expression of one very imp0l1ant transcriptional 
regulator of myelin genes, Krox-20, but not Oct-6, another major 
transcriptional regulator of the myelination process (Darbas et aI., 2004). 
More recently, the elp mutation has been identified as a 225bp inse11ion in 
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the Lgi4 gene. This gene codes for a secreted and glycosylated leucine-
rich repeat protein that is expressed in Schwann cells and in restricted 
populations of neurons. The elp mutation perturbs Lgi4 mRNA splicing, 
precluding splicing of exon 4 of Lgi4 and generating a mutated protein 
that is retained within the cell. Functional studies performed in sensory 
neuron-Schwann cell cocultures, where Lgi4 was downregulated using 
siRNA, identified Lgi4 as an important signalling molecule that controls 
axon sorting during peripheral nerve myelination: in fact, when siRNA for 
Lgi4 in turned-off in cocultures, myelination is inhibited; in addition, 
administration of Lgi4 to elp/elp neuron-Schwann cell cocultures is able to 
restore myelination (Bermingham et al., 2005). Given the phenotype 
similarities between the elp/clp and POQ215X heterozygous mice, one 
might speculate that PO Q215X alters normal Lgi4 function. 
3.3 Q215X1+ mice present a neuromuscular defect 
Using the Rotarod test we next demostrated that this transient 
defect in the process of myelination we showed, resulted in a 
developmental motor deficit. These data, together with previous 
morphological observations in peripheral nerves, lead us to conclude that 
the Q215X heterozygous mice are a partial model of Congenital 
Hypomyelination neuropathy; partial in the sense that they present a 
dysmyelinating phenotype that appears very early in postnatal life and that 
results in a motor disability for the mice, as has been reported for the two 
patients presenting Q215X de novo mutations. Nevertheless, this 
dysmyelination is less severe if compared to the clinical and pathological 
picture of the patients. The possible reasons for this have been already 
discussed in the previous paragraphs and relate to dosage and efficient 
transcription of the mutated allele. However, it is also true that having no 
expression data from human patients, we can not be certain that the less 
severe phenotype we observed in our mouse model could be due to 
intrinsic differences in the control of the myelination process, or, more 
generally of the transcription machinery, between mice and men. In 
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support of the inefficient dosage hypothesis, we have demonstrated that 
the Q215X mutation is manifesting its phenotype through a Gain of 
Function mechanism. As shown in paragraph 1.9.2.2, we have investigated 
the mechanism of action of different PO mutations and we have found it to 
be always dose-dependent. In addition, we have generated homozygous 
Q215X mutant mice: those mice express more mutant protein and present 
a more severe phenotype, as compared to heterozygous (Fig. 2.9 and data 
not shown). Thus, we can speculate that Q215X1+ mice are less severely 
affected than Q215X1+ humans, due to the LoxP-induced reduction of the 
expression of the mutated allele. Although the phenotype we have 
described is milder, it is Congenital Hypomyelination-like, suggesting that 
this could be useful to elucidate the cell biological pathophysiology 
underlying Q215X neuropathy. 
3.4 Q215X MPZ is not trafficked correctly 
We then decided to investigate the pathogenetic mechanism 
through which the mutated protein is able to produce the aberrant 
phenotype. We determined the intracellular location of the Q215X MPZ, 
together with its glycosyltion status. With both analysis, we found that 
most of PO Q215X could be located in the ER or Golgi, but a portion of it 
may arrive to the myelin sheath. These data let us speculate that PO 
Q215X may in part arrive to inappropriate locations, thereby generating 
the radial sorting defects we have described. 
Recently (Wrabetz et aI., 2006), we investigated gain of abnormal 
function also in mouse models of CMTI Band Dejerine-Sottas syndrome 
(DSS) mutations. We have chosen two different mutations in the same 
aminoacid S63, conserved from fish to human (Kirschner et aI., 2004): 
POS63del, associated with CMTIB (Kulkens et aI., 1993) and POS63C is 
associated with DSS (Hayasaka et a1., 1993). We produced transgenic 
mouse models with these alleles and we showed that both alleles produce 
gain of function, but of different types, originating from diverse 
intracellular locations. In particular, our immunohistological analyses 
106 
revealed that POS63C arrived to the myelin sheath, whereas POS63dei is 
mostly retained in the ER. In addition, to better characterize the 
intracellular location of the mutant proteins, we analyzed the glycosylation 
of both POS63dei and POS63C, using the same approach reported for 
Q215X PO. After EndoH or PNGaseF digestion, Western Blot analysis of 
mutant nerve protein lysates demonstrated that POS63C is glycosylated 
like WT, consistent with arrival to myelin sheath, whereas the majority of 
POS63del is not glycosylated and completely resistant to any glycosidase 
treatment, consistent with ER retention. 
Thus, the evidences of mislocalization of Q215XPO that are 
reported in my thesis provide further support to the idea that wide-ranging 
MPZ-related neuropathy phenotypes result from different kinds of Gain of 
Abnonnal Function, originating from diverse intracellular locations 
(Wrabetz et aI., 2006). 
3.5 Conclusions 
In this manuscript we have described the generation and 
characterization of a mouse model of Congenital Hypomyelination 
neuropathy, due to a mutation, Q215X, in the cytoplasmic tail of PO 
glycoprotein. By using homologous recombination into ES cells, we have 
inserted the C to T transition in exon 5 that generates the Q215X mutation 
into one endogenous allele of the mouse mpz gene. Then, we have 
generated a mouse carrying the mutated allele in heterozygosity. We 
analyzed the expression of PO in Q215X1+ mice and we showed for the 
first time that the mutation was effectively translated into a shorter fonn of 
PO glycoprotein, with a lower molecular weight, as compared to wild type 
protein. Morphological observations in sciatic nerves, together with the 
analysis of neuromuscular defects in the transgenic animals lead us to 
three main conclusions. First of all the Q215X heterozygous mice are a 
partial model of Congenital Hypomyelination neuropathy; in fact the 
animals present a dysmyelinating phenotype that appears very early in 
postnatal life and that results in a motor disability for the mice, as has been 
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reported for the two patients presenting Q215X de novo mutations. 
Nevertheless, this dysmyelination was less severe if compared to the 
clinical and pathological picture of the patients. The possible reasons for 
this mild phenotype have been already discussed in the previous 
paragraphs and relate to dosage and inefficient transcription of the mutatcd 
allele. Secondly, by comparing the phenotype of our PO mutant mouse 
with the one of PO +/- mice, we demonstrated that the Q215X mutation is 
acting through a Gain of Function mechanism. Finally, by analyzing the 
intracellular location of the mutated PO glycoprotein and by comparing it 
with the ones of other PO mutant protcins, we have provided further 
support to the hypothesis that the wide-range of neuropathy phenotypes 
due to mutations in MPZ come from different kinds of Gain of Abnormal 
Function, originating from diverse intracellular locations. 
In addition to these findings on the molecular pathogenesis of 
Q215X MPZ Congenital Hypomyelination Neuropathy, the detailed 
morphological analysis of altered radial sorting in sciatic nerves of Q215X 
+/- mice suggests that Q215X may perturb the laminin signalling 
pathways andlor alter normal Lgi4 function, that are necessary for the 
correct spatial and temporal occurrence of radial sorting ofaxons by SC, 
within peripheral nerves. 
Finally, during the process of accomplishing a careful 
characterization of our Q215X mutant mice, we generated a control mouse 
(LoxP mouse), that carries the LoxP site in intron 5, but not the Q215X 
mutation in exon 5. We then found that the LoxP site by itself had an 
effect on PO mRNA stability, reducing its amount as compared to a 
wildtype PO allele. Interestingly, this is the first time that such an effect of 
the LoxP insertion on mRNA steady state has been reported. This effect of 
the LoxP site within intron 5 can explain why the Q215X1+ mice show a 
very mild phenotype compared to patients' clinical picture. In fact, 
recently in Dr. Wrabetz's lab, RNA obtained from skin biopsies taken 
from glabrous myelinated-tiber-containing surfaces of the finger and 
forearm of a patient carrying a Q215X de-novo mutation and from the 
mother as a control was extracted and retro-transcribed. By RT -PCR, a 
149 bp fragment extending from exon 4 to exon 6 was amplified using the 
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same primer pair on patient and control cDNA and on Q2I5X/+ mouse 
and WT cDNA. Contribution from the mutated and normal allele was 
evaluated with BsoFI digestion, since in both the human and mouse 
sequence context, the C to T transition abolishes a BsoFI restriction site. 
This analysis confirmed the reduced expression of the mutated allele in the 
mouse model, previously shown in the thesis, while in the patient the two 
alleles showed similar levels of expression. These data taken together with 
the ones, discussed in paragraph 3.1, demonstrating that the mutation itself 
was not able to induce any reduction in PO mRNA, strongly support our 
idea that the milder phenotype of our Q215X1+ mice, compared to 
patients' clinical picture, is due to the low expression of our transgene, 
carrying the LoxP in intron 5. 
During the last year, new techniques have been validated to create 
transgenic, knock-in and knock-out mice (Copeland et aI., 2001); in 
particular, the development of phage based homologous recombination 
systems made the generation of transgenic and knockout constructs 
simpler, enabling scientists to engineer large segments of genomic DNA, 
like those carried on bacterial artificial chromosomes (BACs) or PI 
artificial chromosomes (PACs) that replicate at low-copy number in 
Escherichia coli. This technicque, which takes advantage of phage 
recombination to perform genetic engineering, is called recombinogenic 
engineering or recombineering: it offers exciting opportunities to create 
mouse models of human disease and for gene therapy. The most important 
aspects of recombineering are that only short homology segments are 
required to direct the recombination, and recombination efficiency rates 
allow recombinants to be screened rather than selected. The fact that 
recombinants can be screened means that only one recombination step is 
required to create the desired modification. These plasmid and phage 
systems possess a high frequency of recombination, offering the 
possibility to manipulate the DNA without any drug selection. With this 
technique, virtually any kind of mutation can be engineered into a BAC in 
the absence of drug-selectable markers or of 10xP or FRT sites, the 
presence of which, as we have clearly seen in our Q215X mutant mice, 
can affect the function of the region of the BAC being studied. 
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4. MATERIALS AND METHODS 
4.1 Production of Targeting Vector 
The complete Mpz was cloned from a a A-DASH II mouse (129S2 strain) 
genomic DNA library, a generous gift from Andras Nagy (Mount Sinai 
Hospital, Toronto, Canada), and subcloned into pBluescript SKII 
(Stratagene, La Jolla, USA), in order to obtain the Mpzblue plasmid. To 
generate the Q215X targeting vector, a 2.6-kb BsrGI fragment, containing 
exons 2, 3, 4 and 5 and part of intron 5 was excised from Mpzblue, blunted 
and subcloned into blunt pBluescript (EcoRI digested and subsequently 
filled-in), to generate the plasmid SAwtblue. Polymerase chain reaction 
(PCR)-based, site-directed mutagenesis (Ho et al., 1989) was performed 
on an Ncol-EcoRV fragment of SAwtblue, in order to introduce the 
mutated eDNA sequence in exon 5. After sequence confim1ation, the 2.6-
kb SmaI-EcoRV mutated fragment was excised from the resulting plasmid 
(SAo2Isxblue) and subcloned into a SmaI digested pLOX plasmid (kind 
gift of Dr. P Orban), 5' to a floxed neo selection minigene present in 
pLOX, to obtain the plasmid SAo215XLOX. A 4-kb BsrGI-SalI fragment 
containing part of intron 5 exon 6 and flanking sequence was excised from 
Mpzblue and subcloned 3' to the floxed neo cassette, into SalI-BsrGI 
digested SAQ215XLOX, in order to generate a new plasmid termed 
SA+1I2LAQ215XLOX. Finally, to obtain the complete Targeting Vector, to 
be used for homologous recombination in ES cells, a 4-kb BsrGI fragment 
was excised from Mpzblue and subcloned into BsrGI digested 
SA+ 1I2LAQ215XLOX plasmid. The resulting TV Q215X plasmid was 
linearized using NotI endonuclease and electroporated into ES cells. In 
order to construct the TV wI for the generation of the control LoxP mouse, 
we used the same strategy, except that the 2.6 BsrGI fragment was not 
mutated. 
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4.2 Generation of recombinant embryonic stcm (ES) cells 
ES cells (TBV2 line - Corradi, 2003) were grown in Dulbecco's Modified 
Eagles Medium (DMEM) 15% fetal calf serum, 10-4 M B-mercaptoethanol 
(all from GIBCO Industries, Langley, OK, US), 2 mM L-Glutamine and 
107 Ulml LIF (CHEMICON Int.- Temecula, CA, US), on an embryonic 
fibroblast feeder layer previously inactivated with Mitomycin C. 
Electroporation and positive selection were performed as described 
(Joyner, 1993). Resistant colonies were picked after 8-10 days of selection. 
Genomic DNA was extracted from expanded clones, digested with HindUI 
and analyzed by Southern blotting at the 5' end of the recombinant locus 
(see Fig.lA for external probe). Homologous recombinant clones were 
analyzed at the 3' end by HindIU and BglII digestion and semi-quantitative 
Southern analysis, for copy number monitoring. Out of 168 ES clones 
screened, one scored positive for Q215XNEO homologous recombination 
and was propagated. 2 clones, out of 190, scored positive for LoxP 
homologous recombination and were propagated. The Q215XNEO 
positive clone was screened for the presence of the mutation by PCR 
analysis, using intron 4 and intron 5 specific primers (5'-
CCCTAGACTGCTTCAGTGGTGG-3 ' and 5'-
GGTCAGCCTTGGGCTTGAC-3' respectively), followed by restriction 
with BsoFI endonuclease (Fig.l C). PCR conditions were 95°C for 30s , 
55°C for 60s and 72°C for 30s (30 cycles), followed by 10 min extension 
at 72°C, in a standard PCR reaction mix. 
4.3 Generation of chimeric micc and germline transmission of the 
Mpz targeted allele 
All experiments perfonned on mice were conducted with appropriate 
anaesthesia, in accordance with experimental protocols approved by the 
Institutional Animal Care and Use Committee, San Raffaele Scientific 
Institute and the Italian ministry of Health. The targeted ES clones were 
injected into blastocysts derived from C57BLl6J females. The chimeric 
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embryos were then transferred into the uteri of 2.5 day pseudopregnant 
foster mothers. Chimeric males with 70-100% agouti color were bred by 
crossing with wild-type C57BLl6J females and germline transmission was 
identified by the presence of agouti offspring. Genotyping was carried out 
by multiplex PCR amplification with one primer in intron 4, another one 
in exon 6 and the third one on the neomycin minigene (respectively: 5'· 
CCCTAGACTGCTTCAGTGGTGG·3' , 
GGTGCTTCGGCTGTGGTCC·3 ' and 
5'· 
5'· 
CAATGACGACGCTGGGCGGGG·3'). PCR conditions were 95°C for 
60s, 68°C for 60s and 72°C for 120s (32 cycles), followed by 10 min 
extension at 72°C, in a standard PCR reaction mix. Heterozygous mice for 
the Q215XNEO allele were subsequently confirmed by Southern blotting 
using the 5' probe. In order to remove the neomycin minigene, we then 
crossed Q215XNEO heterozygous mice with transgenic mice expressing 
the Cre recombinase under control of the human cytomegalovirus minimal 
promoter (Schwenk et aI., 1995). We obtained neo negative, Q215X 
heterozygous mice, that were then crossed to homozygosity. Genotyping 
of these mice was carried out by PCR using intron 4 and exon 6 specific 
primers that flanked the remaining LoxP site in intron 5. Both Southern 
blot and PCR analyses were performed on genomic DNA prepared from 
tail samples (Sambrook et aI., 1985). Q215X heterozygous mice were then 
maintained by backcrosses to FVBIN mice (Charles River Lab.). Animals 
used for most experiments were congenic N 5 to NIl in FVBIN 
background. 
4.4 Western Blot Analysis 
Frozen sciatic nerves dissected from P28 Q215X heterozygous, 
homozygous and wild type mice were pulverized, sonicated in lysis buffer 
(95 mM NaCI, 25 mM Tris-HCI, pH 7.4, 10 mM EDTA, 2% SDS, and 
protease inhibitors), boiled for 5 min, and spun at 14,000 rpm in a 
microcentrifuge for 10 min at room temperature to eliminate insoluble 
material. The protein concentration in supernatants was determined by 
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BioRad protein assay according to the manufacturer's instructions. Equal 
amounts of homogenates (containing 2.5-10 Ilg of protein) were brought 
up to 5 III with 8 M urea, to which was added 5 III of 8 M urea, 0.05 M 
OTT, 1 %SOS, followed by 10 III of standard reducing sample buffer. The 
samples were denatured, resolved on a 14% SOS-polyacrylamide gel, and 
electroblotted onto PVOF membrane. To verify equal loading of protein, 
membranes were stained with amido black or ponceau red. Blots were then 
blocked with 0.05% Tween, 5% dry milk in PBS, and incubated with the 
appropriate antibody in 0.05% Tween and 1 % dry milk in PBS. Mouse 
mAbs recognized PO (P07, the generous gift of Dr. Juan Archelos, 
Department of Neurology, Karl-Franzens-Universitat, Graz, Austria; 
Archelos et al. 1993) and B-tubulin (Sigma Chemical Corporation, St. 
Louis, MO, US). Peroxidase-conjugated secondary antibodies (Sigma 
Chemical Corporation, St. Louis, MO, US) were visualized using the ECL 
method with autoradiography film (Amersham Biosciences AB, Uppsala, 
Sweden). The intensity of bands was quantified by densitometry, and the 
ratio of intensities for each myelin protein and B-tubulin was determined. 
For deglycosylation experiments with peptide N-glycosidase F (PNGaseF) 
and endoglycosidase H (EndoH), homogenates were digested per 
manufacturer's instructions (New England Biolabs, Beverly, MA) and 
visualized as described above. 
4.5 Semi-quantitative RT -peR 
Sciatic nerves were dissected from mutant and control littermates at the 
ages indicated (n=3 mice/genotype/time point). Total RNA was isolated 
using the triazol reagents (Boehringer Mannheim, Mannheim, Germany) 
with minor modification. Nerves were homogenized in the presence of 
triazol, extracted with chloroform and precipitated in the presence of 
tRNA. A portion (500 ng) of total RNA was reverse transcribed using 
Moloney Murine Leukaemia Virus reverse transcriptase and oligo dT 
primers (Promega Corporation, Madison, WI, US). For analysis in sciatic 
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nerves, equal volumes of the reverse-transcribed product from nerves of 
mutant and control mice were amplified using GAPDH-specific primers 
(5'-GTATGACTCTACCCACGG-3' and 5'-
GTTCAGCTCTGGGATGAC-3') in the presence of alpha 32p_dCTP. PCR 
conditions were 95°C for 30s, 55°C for 60s and 72°C for 60s (30 cycles), 
followed by 10 min extension at 72°C, in a standard PCR reaction mix. 
Aliquots from the amplification were withdrawn at 22, 24 and 26 cycles, 
resolved on an acrylamide gel and visualized by autoradiography. The 
intensity of the bands was quantified by densitometry (Molecular 
Dynamics), to verify that amplification was logarithmic, and to determine 
the relative amount of starting cDNA from each sample. Equal amounts of 
RT product, as detem1ined by the GAPDH signal, were amplified using PO 
specific primers. Analysis of the products was conducted as for GAPDH. 
To analyse PO expression in LoxP and wild type mice, we exploited the 
exon 3 polymorphism using the RT-PCR method of Fiering et al. (1995), 
as described in Wrabetz et al. (2000). Briefly, 200 ng of total RNA was 
reverse transcribed, PCR amplification was performed as described above 
in the presence of alpha 32p_dCTP, using a single primer pair recognizing 
Po ex on 2 (5'-GTCCAGTGAATGGGTCTCAG-3') and exon 4 (5'-
GCTCCCAACACCACCCCATA-3') that flank a polymorphic DpnII site 
present only in the C57BLl6J allele and not in 129S2Pas (the polymorphic 
BglII site spans the intron 2/exon 3 boundary, such that in the cDNA 
product, only its 4 nucleotide core, a DpnII site, remains). PCR conditions 
were 95°C for 30s, 63°C for 60s and 72°C for 60s (26 cycles), followed by 
10 min extension at 72°C, in a standard PCR reaction mix. To avoid the 
formation of heteroduplexes between the DpnII-containing and non-
DpnII-containing products, only cycles in the logarithmic range were 
chosen. Two microlitres of RT-PCR product were digested with DpnII for 
60 min, phenol extracted, precipitated, resolved by acrylamide gel 
electrophoresis and visualized by autoradiography. The intensity of the 
bands was quantified by densitometry, and the ratio between DpnII-
containing (from wild type mice) and non-DpnII-containing (from LoxP 
mice) products was calculated. The procedure described above was 
repeated three times to confirm reproducibility of the data presented. To . 
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analyse PO expression in Q215X mice, we took advantage of the BsoFI 
site that disappear when the C to T transition in exon 5 is present. We used 
the RT-PCR method of Fiering et al (1995) described above. We 
perfonned PCR amplification using a PO specific primer pair that flanks 
the Q215X mutation in exon 5 (in exon 4: 5'-
GGCAGGCTGCCCTGCAG-3' and in exon 6: 5'-
CTTCTCACTGGCAGCTTTGGTGC-3'), in the presence of 32p_dCTP. 
PCR conditions were 95°C for 30s, 63°C for 30s and noc for 30s (26 
cycles), followed by 7 min extension at noc, in a standard PCR reaction 
mix. The RT-PCR products were digested with BsoFI for 60 min, phenol 
extracted, precipitated, resolved by acrylamide gel electrophoresis and 
visualized by autoradiography. The intensity of the bands was quantified 
by densitometry, and the ratio between BsoFI-containing (from wild type 
Mpz allele) and non-BsoFI-containing (from Q215X allele) products was 
calculated. The procedure described above was repeated three times to 
confinn reproducibility of the data presented. 
4.6 Morphological Analysis 
Mutant and control littennates were sacrificed at the ages indicated and 
sciatic nerves were dissected. In most cases, semi-thin section and electron 
microscope analyses of sciatic nerves was perfonned as described in 
Quattrini et aI., 1996. For semi-thin analysis, a portion of the nerve was 
fixed in 2% buffered glutaraldehyde and post fixed in 1 % osmium 
tetroxide. After alcohol dehydration, these samples were embedded in 
Epon. Transverse sections (0.5-1 )..lm thick) were stained with toluidine 
blue and examined by light microscopy. Ultra-thin sections were stained 
with uranyl acetate and lead citrate and examined by electron microscopy. 
Morphometric features in electromicrographs were detennined using NIH 
ImageJ software (http://rsb.info.nih.gov/ijl). 
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4.7 Behavioral Analysis 
For Rotarod analysis, groups of PIO mutant and control littermates were 
placed on a round cylinder rotating first at 4 rotations per minute (rpm) 
and then accelerating at 7.2 rpm2 (Ugo Basile, VA, Italy). The animals 
were allowed to stay on the rod for a maximum of 900 s and the time of 
hold on the rotating rod was measured in subsequent trials (2 trials per day 
from PIO to PI2). Statistics was made using SigmaStat 3.0 software. 
4.8 Immunohistochemistry 
For cryosections, sciatic nerve segments from mutant and control animals 
were collected in PBS and either directly, or after overnight fixation in 4% 
paraformaldehyde in O. I M PBS at 4°C, cryoprotected in 20% sucrose, 
embedded in a.C.T. (Miles), and snap-frozen in liquid nitrogen. Indirect 
immunofluorescence was performed on 10-l1m thick cryosections fixed 
again in 4% paraformaldehyde in O.IM PBS for 4 min and in cold acetone 
for lOsee, rinsed twice in PBS, and blocked with 10% normal goat serum 
(Dako, Glostrup, Denmark), 1 % bovine serum albumin, 0.1 % Triton X-
100 and 0.05% sodium azide. Double staining was performed with a rabbit 
polyclonal Ab recognizing PO extracellular domain (a gift from Dr.D. 
Colman, Montreal Neurological Institute, Montreal, CA) and a 
monoclonal Ab recognizing the KDEL tetrapeptide at the carboxy-
terminal sequences of ER-resident proteins (StressGen, Victoria, BC, 
Canada). Sections were then treated with FITC- or TRITC-conjugated 
secondary antibodies (Southern Biotechnology Associates, Inc., 
Birmingham, AL, US), and viewed with a fluorescence microscope. 
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4.9 Image Analysis 
Micrographs of morphological samples and radiographic films were 
digitalized using an AGF A Arcus 2 scanner and figures were prepared 
using Adobe ® Photoshop 7.0. 
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